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Abstract 
Since cancer is the second most common cause of death in the United States, it is 
of great importance to pursue new and improved methods for treating cancer.  The goal 
of cancer immunotherapy is to exploit the specificity and longevity of immune responses 
through the use of vaccines to treat cancer.  DNA vaccines have many advantages over 
protein and viral vaccine-based strategies including low cost, ease of production, 
flexibility and low toxicity.  Plasmid DNA vaccines encoding tumor antigens can 
produce powerful anti-tumor immune responses in animal models, but clinical trials have 
shown only modest responses.  This lack of clinical efficacy is thought to reflect the two 
major limitations of plasmid DNA vaccines: transient protein expression and low 
transfection efficiency.  Transient protein expression is likely the result of gene silencing 
due to transcriptionally repressive chromatin within the plasmid backbone.  To overcome 
this limitation, we removed the bacterial backbone sequences and produced a minicircle 
DNA consisting of the gene expression cassette with only a few bases of the bacterial 
backbone.  This resulted in persistent protein expression, increased transfection efficiency 
and enhanced immunogenicity.  In an effort to further enhance the transfection efficiency, 
we produced cationic carriers that bind plasmid DNA and protect it from degradation.  
The addition of these cationic carriers significantly increased transfection efficiency in 
vitro but has yet to show the same effect in vivo.  Additionally, we administered these 
vaccines transdermally using a tattoo device and achieved rapid and potent immune 
responses.  Our results suggest transdermal delivery of a minicircle DNA vaccine elicits 
potent antigen-specific immune responses, and as such, holds great promise for cancer 
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therapy.  Future work will include increasing transfection efficiency in vivo and 
increasing the immunogenicity of the vaccines through the use of adjuvants with the goal 
of producing feasible, efficacious DNA vaccines for cancer therapy. 
  v 
Table of Contents 
Acknowledgements         i  
Dedication          ii 
Abstract          iii 
Table of Contents         v 
List of Figures          vii 
List of Abbreviations         ix  
 
Chapter 1: Introduction        1 
 Cancer Therapy        1 
 Cancer Immunotherapy       1 
Immunity and Cancer        1 
 Humoral Immunity        3 
 Cell-mediated Immunity       3 
 Recognition of Tumors by the Immune System    4 
 Cancer Vaccines        5 
 Adjuvants         8 
 Vaccination Methods        10 
 Synthetic Vehicles for DNA Vaccination/Carrier Proteins   11 
 Thesis Statement        12 
 Figures         14 
Chapter 2: Preliminary DNA Vaccine Research     20 
 Introduction         20 
  vi 
 Materials and Methods       24 
 Results         29 
 Discussion         33 
 Figures         37 
Chapter 3: Minicircle Vaccines       52 
 Introduction         54 
 Materials and Methods       55 
 Results         62 
 Discussion         67 
 Acknowledgements         70 
Figures         72 
Chapter 4: Cationic Carriers        86 
 Introduction         86 
 Materials and Methods       88 
 Results         94 
 Discussion         96 
 Figures         99 
Chapter 5: Concluding Remarks       109 
Bibliography          113 
  vii 
List of Figures 
Chapter 1 
 Figure 1: DNA vaccination and the resulting immune response  14 
 Figure 2: Structure of heat shock protein 70 (Hsp70)   16 
 Figure 3: Immunostimulatory properties of heat shock proteins  18 
Chapter 2 
 Figure 1: pWMD plasmid constructs       37 
 Figure 2. Protein expression and secretion in 293T cells   42 
 Figure 3. DNA tattooing procedure      44 
Figure 4: Antigen specific CD8+ T cell response to pWMD2S following DNA 
tattooing         46 
Figure 5: Functional antigen specific CD8+ T cell response with and without the 
secretion sequence       48 
Figure 6: Antigen specific CD8+ T cell response following one, two or three 
immunizations        50 
Chapter 3 
 Figure 1: Minicircle derivation      72 
 Figure 2: Enhanced expression of minicircle-encoded eff in vitro  74 
Figure 3: Enhanced intensity and duration of minicircle-encoded eff expression in 
the skin        76 
Figure 4: Enhanced presentation of minicircle-encoded antigen by dendritic cells 
          78 
  viii 
Figure 5: Enhanced activation of antigen-specific CD8+ T cells in vivo following 
immunization with MC-Ag      80 
Figure 6: Enhanced cytolytic activity of antigen-specific CD8+ T cells following 
immunization with MC-Ag      82 
Chapter 4 
 Figure 1: Protein sequence, expression and purification   99 
 Figure 2: DNA binding ability of +36GFP and +36GFP-HA2  101 
 Figure 3: Ability of +36GFP and +36GFP-HA2 to bind cells in vitro 103 
Figure 4: Transfection efficiency of +36GFP and +36GFP-HA2 in vitro using a 
luciferase-encoding plasmid      105 
Figure 5: Transfection efficiency of +36GFP-HA2 in vivo   107 
 
 
 
 
 
  ix 
List of Abbreviations 
APC: Antigen presenting cell 
Ag: Antigen 
BpA: Bovine growth hormone polyadenylation signal 
CFA: Complete Freund’s adjuvant 
CFSE: 5-(and-6)-carboxyfluorescein diacetate, succinimidyl ester 
CTL: Cytotoxic T lymphocyte 
DC: Dendritic Cell 
dLN: Draining lymph node 
DNA: Deoxyribonucleic acid 
eff: Enhanced firefly luciferase  
EGFR: Epidermal growth factor receptor 
ELISA: Enzyme-linked immunosorbent assay  
ELISpot: Enzyme-linked immunosorbent spot assay 
EMSA: Electrophoretic mobility shift assay 
FL: Full-length 
FL-Ag: Full-length plasmid encoding the antigen cassette 
FL-eff: Full-length plasmid encoding enhanced firefly luciferase 
GFP: Green fluorescent protein 
HA2: Hemagglutinin 2 
His: Histidine 
HPV: Human papilloma virus 
  x 
Hsp: Heat shock protein 
Hsp70: Heat shock protein 70 
hUBC: Human ubiquitin C promoter 
IFN-γ: Interferon-γ 
MC: Minicircle 
MC-Ag: Minicircle encoding the antigen cassette 
MC-eff: Minicircle encoding enhanced firefly luciferase 
MHC: Major histocompatibility complex 
NK: Natural killer 
NP: Nucleoprotein 
OVA: Ovalbumin 
PBS: Phosphate buffered saline 
pDNA: Plasmid DNA 
SDS: Sodium dodecyl sulfate 
SDS-PAGE: Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
TCR: T cell receptor 
UbC: Ubiquitin C promoter 
VC: Empty control vector 
VEGF: Vascular endothelial growth factor 
 
 
 
  1 
Chapter 1: 
Introduction 
Cancer therapy: 
 It is predicted that 1,529,560 new cancer cases and 569,490 deaths will occur in 
the United States alone in 2010 (1).  Despite recent advances in cancer therapy, currently 
one in four deaths in the United States is caused by cancer.  This high mortality rate is 
mainly due to recurrence following standard treatments including surgery, radiation 
and/or chemotherapy.  Therefore, there is a great need for more effective cancer 
treatment strategies.  Imunotherapy, or using the immune system to kill cancer cells 
selectively, may be one answer.       
 
Cancer immunotherapy: 
Immunity and cancer 
 The immune system protects an individual against disease or infection due to 
pathogens such as bacteria and viruses.  Immunosurveillance is the theory that the 
immune system also protects individuals against tumor formation by detecting and killing 
nascent tumor cells.  Strong evidence for this theory comes from data showing that 
RAG2-/- mice (which lack both T and B cells) have a higher rate of spontaneous tumors 
than immunocompetent mice (2).  In addition, Shankaran and colleagues showed that the 
tumor rate was even higher in RAG2-/- mice that also lacked interferon type I and type II 
signaling.    
 There are two types of immune responses: innate and adaptive.  The innate 
immune system serves as a first line of defense and functions in the non-antigen-specific 
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killing of pathogens and virus-infected cells.  Innate immune cells include granuloctyes, 
mast cells, natural killer cells, macrophages and dendritic cells (DCs).  There are three 
types of granulocytes: neutrophils, eosinophils and basophils.  Neutrophils, the most 
common of the granulocytes, are phagocytic cells that engulf and destroy extracellular 
bacteria.  Eosinophils kill parasites that are coated with antibodies while basophils likely 
function in allergic responses.  Mast cells trigger local inflammatory responses and also 
function in allergic responses by releasing granules that contain histamine.  Natural killer 
cells release lytic granules that can kill some virus-infected or tumor cells.  Macrophages 
are phagocytic cells and can also act as antigen presenting cells (APCs).  APCs take up 
antigens and display them on their cell surface along with either major histocompatibility 
complex (MHC) class I or MHC class II molecules. DCs are specialized APCs whose 
primary role is to take up, process and present antigen to T cells, resulting in an adaptive 
immune response.   
Unlike innate immune responses, adaptive immune responses develop slowly 
(over the course of days) and are antigen-specific and long-lived.  The adaptive immune 
system was named due to the nature of the responses to adapt throughout the life of the 
individual due to infection and disease.  The adaptive immune system consists of T and B 
lymphocytes.  The antigen-specific receptors displayed by these cells are produced 
through somatic rearrangements of germline-encoded gene segments.  The combinatorial 
assembly of multiple gene segments, plus the inexact nature of the joining process, leads 
to a great diversity of specificities.  This diverse repertoire enables T and B lymphocytes 
to detect a virtually limitless array of antigens.  In addition, memory T or B cells remain 
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after primary immune responses, leading to faster secondary responses and immune 
memory.  It is due to the specificity and long-lived memory responses that 
immunotherapy is so attractive for cancer treatment. 
 
Humoral immunity 
 Humoral immunity is mediated by antibodies secreted by terminally differentiated 
B cells.  Surface immunoglobulin expressed on B cells can recognize extracellular 
pathogens including bacteria, fungi and parasites.  B cells require two signals for 
activation: the binding of the antigen to the B cell receptor and an additional signal such 
as one from a CD4+ helper T cell.  Once activated, the B cell proliferates and 
differentiates into a plasma cell that secretes antibodies.  These antibodies can bind 
extracellular toxins or pathogens, leading to their ingestion and destruction by 
macrophages or they can bind extracellular pathogens and activate complement leading 
to pathogen lysis or ingestion.   
 
Cell-mediated immunity 
 Cell-mediated immunity in the adaptive immune system is composed of both 
CD4+ and CD8+ T cells.  CD4+ T cells, which include helper T cells and regulatory T 
cells, recognize peptides presented by MHC Class II molecules.  These peptides are 
typically derived from the proteolysis of internalized, extracellular proteins.  Regulatory 
T cells play a role in suppressing the immune system whereas helper T cells aid in the 
activation of CD8+ T cells, B cells, macrophages and DCs.  CD8+ T cells, which 
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differentiate into cytotoxic T lymphocytes (CTLs), recognize peptides presented on MHC 
Class I, which include intracellular proteins including those produced in virus-infected 
cells and tumor cells.  CD8+ T cells kill target cells by release of cytotoxins such as 
perforins, granzymes and granulysins.  Perforins form pores in the target cell’s plasma 
membrane, allowing granzymes to enter the cell, leading to caspase activation and 
apoptosis.  Granulysin leads to pore formation and apoptosis of the target cell and has 
antimicrobial function.  Additionally, CD8+ T cells can to kill cells through 
receptor/ligand interactions such as the binding of Fas ligand on their cell surface with 
Fas on the target cell.  This interaction between Fas ligand and Fas leads to caspase 
activation and apoptosis of the target cell.  The TRAIL pathway is another mechanism of 
receptor mediated killing by effector CD8+ T cells.  Since CD8+ T cells can recognize 
and kill tumor cells, they are often the target of cancer immunotherapy approaches.  
 
Recognition of tumors by the immune system 
 The adaptive immune system responds to tumor cells via recognition of tumor-
specific or tumor-associated antigens.  Tumor-specific antigens are only expressed by 
tumor cells and not by normal cells while tumor-associated antigens are differentially 
expressed by tumor cells versus normal cells (3).  Tumor-specific antigens include 
proteins produced by mutations caused by carcinogens (4) and by viral proteins, such as 
E6 and E7 of the human papillomavirus, in viral-induced tumors (5).  Examples of tumor-
associated antigens include tyrosinase (6), human epidermal growth factor receptor 2 
(HER2)/neu (7), prostate-specific antigen (PSA) (8) and gp100 (9). 
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 Following tumor cell death, tumor antigens can be internalized by APCs such as 
DCs, which are constantly sampling the extracellular fluid.  The APC can then process 
and present peptides derived from the antigen on MHC Class I along with co-stimulatory 
molecules on its cell surface.  A CD8+ T cell bearing a T cell receptor (TCR) specific for 
that MHC Class I:antigen complex can then be  activated.  Following activation, the 
CD8+ T cell proliferates and differentiates into a CTL.  It can then travel to the site of the 
tumor and release cytotoxins to kill the tumor cells that express its specific antigen.  
Additionally, following expansion and contraction of this particular CD8+ T cell clone; 
memory CD8+ T cells will remain and respond if the tumor recurs.       
 
Cancer vaccines:  
Vaccines have been used to prevent bacterial and viral diseases for centuries, but 
only in the last 30 years has their potential for cancer treatment been explored.  There has 
been investigation into both prophylactic and therapeutic cancer vaccines.  Vaccines that 
prevent infection with tumor-associated viruses, such as Hepatitis B virus which can lead 
to hepatocellular carcinoma and human papilloma virus (HPV) which causes cervical 
cancer, have been shown to prevent tumor occurrence (10, 11).  The long-term goal of 
this thesis work is to improve therapeutic cancer vaccines that are aimed at curing 
established tumors.    
There are two types of immunotherapy, passive immunotherapy and active 
immunotherapy.  Passive immunotherapy involves the adoptive transfer of tumor-specific 
antibodies or immune stimulators (such as cytokines), or ex-vivo activated antigen-
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specific CD8+ T cells.  In contrast, the goal of active immunotherapy is to activate the 
patient’s immune system through a vaccine consisting of either tumor-specific or tumor-
associated proteins/peptides, live vectors or plasmid DNA encoding tumor antigens, or 
tumor antigen-loaded DCs.  The benefit of active over passive immunotherapy is that it 
results in a long-lasting memory response that can prevent tumor recurrence.  It is the 
goal of cancer immunotherapy to elicit an adaptive immune response due to both its 
specificity (ability to kill tumor cells while leaving normal cells unharmed) and its 
longevity (ability to prevent tumor recurrence).   
There are four broad categories of cancer vaccines: tumor cell lysates and 
derivative proteins, synthetically produced proteins and peptides, live microbial vectors 
and plasmid DNA (12).  Examples of tumor cell vaccines include tumor-antigen loaded 
DCs and ex-vivo activated and expanded tumor-antigen specific CD8+ T cells.  
Production of these DC or CD8+ T cell vaccines is labor-intensive and costly.  Live 
vector vaccines include viral and bacterial vectors and have many advantages including 
high transfection efficiency, high immunogenicity, large variety to choose from and the 
flexibility to modify the gene or genes that they encode.  However, they also have a risk 
of toxicity, possibility of pre-existing immunity and potential for immunity toward viral 
proteins which can decrease their effectiveness.   
Protein and peptide vaccines typically encode 8-10 linear amino acid stretches 
that can be detected by CD8+ T cells.  Protein-based vaccines can contain multiple CD8+ 
T cell epitopes (sequences recognized by the T cell receptor) and can be used with 
multiple adjuvants, but they can be difficult to produce, have low immunogenicity and 
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often elicit better antibody than CTL responses.  Peptide-based vaccines are easier to 
produce, can also contain multiple CD8+ T cell epitopes and the epitopes can be 
optimized for better T cell responses.  However, the T cell epitopes must first be 
discovered and the problem of low immunogenicity remains.   
The protein and peptide group of vaccines includes antibody-based vaccines, a 
specific type of protein vaccine, which has shown great promise in the clinic.  Antibody-
based vaccines consist of antibodies that are specific for tumor antigens or block ligand 
binding and/or signaling of pathways critical for tumor growth including vascular 
endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR).  
Antibody-based vaccines have led to complete tumor regression in many individuals (13).  
Examples of this type of vaccine include Rituximab (non-Hodgkins lymphoma), 
Trastuzumab (breast cancer), and Cetuximab (colorectal cancer along with head and neck 
cancers) (14).   
The final type of cancer vaccines consists of plasmid DNA that encode one or 
more tumor antigens.  DNA vaccines are typically administered either intramuscularly or 
intradermally (15-18).  Following vaccination, resident cells (either myocytes and DCs in 
the case of intramuscular vaccination or keratinocytes and DCs in the case of intradermal 
vaccination) take up the plasmid and express the encoded antigen (Figure 1) (19).  The 
antigen can then be presented to CD8+ T cells either directly by DCs that have been 
transfected with the plasmid or indirectly following the release of antigen from 
keratinocytes or myocytes and their uptake by and presentation on DCs.  The CD8+ T 
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cells are activated, proliferate and migrate to the site of the tumor where they release 
cytotoxins to specifically kill antigen-bearing target cells.  
DNA plasmids have many advantages over proteins and peptides including their 
flexibility (easy to manipulate), ease of production, stability, ability to activate cellular 
and humoral immunity, ability to be administered repeatedly, low cost for production and 
safety (20-22).  There are some limitations, however, which include transient transgene 
expression, low transfection efficiency and low immunogenicity.  Transient transgene 
expression is a result of low levels of protein production and short-lived expression.  The 
aim of this thesis is to test approaches designed to overcome these limitations. 
 
Adjuvants: 
 Adjuvants are substances that enhance an immune response to an antigen.  The 
need for adjuvants was discovered when it was found necessary to add killed bacteria or 
bacterial extracts to antigens to produce adaptive immune responses.  Examples of 
adjuvants include bacterial components such as endotoxin or lipopolysaccharide, 
Complete Freund’s adjuvant (an oil and water emulsion including muramyldipeptide, a 
component of mycobacteria) and aluminum hydroxide gel.  Adjuvants function by 
increasing uptake by APCs, by enhancing the APCs ability to produce an immune 
response through increasing its antigen-presentation or through production of 
inflammatory cytokines.    
One adjuvant is heat shock protein 70 (Hsp70).  Hsp70 belongs to a highly 
conserved, ubiquitous superfamily of stress proteins.  In 1962, Ritossa and colleagues 
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discovered heat shock proteins in Drosophila larvae following thermal stress (23).  In the 
1980’s, Srivastava and colleagues tested fractions of tumor cell lysates for 
immunoprotective effects and found that it was the heat shock proteins that were 
producing these effects (24).   
Hsp70 has three major functional domains: an ATPase domain, a substrate-
binding domain composed of neutral, hydrophobic residues and an alpha-helical C-
terminal domain which acts as lid that helps keep bound peptide in place (Figure 2).  
Hsp70 can be found both intracellularly and extracellularly.  Intracellular Hsp70 
functions in protein folding & transmembrane transport and protects cells from 
environmental stresses including heat, cold and oxygen deprivation (25, 26).  
Extracellular Hsp70 can be membrane-bound or in exosomes and either peptide-bound or 
free.   
It is the extracellular Hsp70 that has immunostimulatory functions (Figure 3) (27).  
Hsp70 is a potent adjuvant that links innate and adaptive immune responses by activating 
and delivering peptides to APCs such as DCs.  To activate T cells fully, DCs must also 
provide costimulatory- and cytokine-derived stimuli that result from receipt of “danger” 
or “stranger” signals.  Hsp70 provides a strong “danger” signal to DCs that leads to 
protective CD8+ T cell-mediated responses in models of viral and tumor immunity (28-
32).  Heat shock proteins have been used for immunotherapy/cancer vaccines in many 
types of cancer, including melanoma, renal cell carcinoma, colon cancer, chronic 
myelogenous leukemia, lymphoma and pancreatic cancer (33)(27).  In addition, an 
HspE7 fusion protein vaccine (Nventa) has been produced (29, 32, 34).   
  10 
 
Vaccination methods: 
Vaccines can be administered subcutaneously, intramuscularly, intravenously or 
intradermally.  The primary methods of vaccination for plasmid DNA vaccines are 
intramuscular or intradermal since the plasmid needs to be taken up by cells for the genes 
to be expressed.  The typical procedure for intramuscular vaccination involves injection 
into the muscle every two weeks for a total of three immunizations.  The immune 
response is then detected two weeks following the last vaccination, resulting in a total of 
six weeks for the optimal response.  Since there are relatively few APCs in muscle tissue, 
it takes longer for a detectable immune response to occur than in other tissues such as the 
skin.   
The skin is a barrier organ relatively rich in APCs. While intradermal vaccination 
still involves three immunizations, they are spaced closer together and the resultant 
response is quicker, typically in less than two weeks total.  The most common device 
used for intradermal immunization is the gene gun (35)(36).  A gene gun is a device that 
shoots gold coated particles into cells using a low pressure helium pulse.  This device was 
designed for transformation of plant cells, but is now commonly used for delivering 
genetic material to all types of cells.  Nanogram amounts of DNA administered using a 
gene gun can elicit humoral and cytotoxic T lymphocyte responses (18).   
In 2005 Bins and colleagues described a DNA vaccination method that employs a 
tattoo device (37).  The rotary tattoo device contained multiple needles, was set to a depth 
of 0.5mm and oscillated at 100Hz.  They administered 20 µg of plasmid in 10 µl of saline 
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solution to a shaved hind leg.  They compared antigen-specific T cell responses elicited 
by tattooing to responses obtained via more conventional routes of DNA vaccination such 
as intramuscular injection and intradermal administration via a gene gun.  The responses 
with tattooing were similar to that achieved with the gene gun, but a tattoo device is 
much cheaper and easier to use.  Compared to intramuscular vaccination, intradermal 
administration via tattooing consistently activated higher frequencies of antigen-specific 
CD8+ T cells and it did so in a shorter time.  The authors suggested the higher frequency 
of APCs in the skin versus the muscle and the greater surface area over which the DNA 
was applied, accounted for this enhanced response.  They determined the optimal 
vaccination via this method was tattooing every three days for three immunizations and 
measuring the CD8+ T cell response six days after the last immunization.  Due to the 
advantages of using a tattoo device for DNA delivery, we use this method for DNA 
immunization.   
 
Synthetic vehicles for DNA vaccination/Carrier proteins: 
 To increase the efficacy of DNA vaccines, synthetic particles have been used as 
carrier systems for the plasmids.  For this, the DNA is either complexed with or 
encapsulated into the synthetic carrier producing micro- or nanoparticles.  This technique 
has been widely used for nucleic acid delivery (38)(39)(40).  Most of these complexes are 
formed by the electrostatic interaction between cationic carriers and anionic phosphate 
groups in the plasmid.  This complex has numerous advantages over naked plasmid DNA 
including protection against endonucleases, increased cellular uptake and increased 
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uptake by APCs.  Examples of synthetic vehicles that have been used for DNA delivery 
include cationic lipids, cationic polymers and non-cationic polymers such as poly(lactide) 
or poly(lactide-co-glycolide). 
 In 2007 Lawrence and colleagues described a mutant, supercharged green 
fluorescent protein (GFP) that had a +36 charge and increased resistance to aggregation 
and consequent precipitation (41).  They further showed that this +36GFP bound DNA 
and led to DNA transfection in vitro.  The use of this protein as a cationic carrier for 
DNA vaccines may increase transfection efficiency.      
 
Thesis Statement: 
Immunotherapy using DNA vaccines is a promising approach for the treatment of 
cancer.  DNA vaccines encoding tumor antigens produce powerful anti-tumor immune 
responses in animal models, but clinical trials show only modest responses.  Although 
DNA plasmids have many advantages including low cost, ease of production, flexibility 
and safety; they also have disadvantages, including transient protein expression and low 
transfection efficiency.  The primary goal of this dissertation research was to overcome 
these barriers and thereby increase the efficacy of plasmid DNA vaccines.    
Chapter 2 of this dissertation shows the prelimary DNA vaccine research 
necessary for the following chapters.  The data show that we can produce and administer 
DNA vaccines and can track the resulting antigen-specific CD8+ T cell responses.  We 
have chosen to administer the vaccines intradermally using a tattoo device in order to 
achieve rapid and potent immune responses. 
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Chapter 3 of this dissertation is focused on increasing both the level and duration 
of protein expression following DNA vaccine immunization.  Transient protein 
expression is likely the result of gene silencing due to transcriptionally repressive 
chromatin within the plasmid backbone.  We overcame this by removing the bacterial 
backbone sequences and thereby producing a minicircle plasmid consisting of the gene 
expression cassette with only a few bases of the bacterial backbone.  This resulted in 
persistent protein expression and in greater resulting immune responses.   
Chapter 4 of this dissertation is focused on overcoming the low transfection 
efficiency previously seen with DNA vaccination.  We produced cationic carriers that 
bind the plasmid and then increase transfection efficiency in vitro.  Further optimization 
of the vaccine strategy may result in highly efficacious DNA vaccines in a clinical 
setting.  
  14 
 
 
 
Figure 1.  DNA vaccination and the resulting immune response (From “DNA 
vaccines: ready for prime time?” (9)).  This diagram shows the process of 
intramuscular immunization with a DNA vaccine and the resulting activation of T cells.  
First, the gene of interest is chosen and the plasmid is constructed.  The vaccine is then 
administered intramuscularly.  Following vaccination, myocytes and some APCs are 
transfected with the plasmid and express the gene of interest.  There are two ways that 
lead to antigen presentation to CD8+ T cells: either by antigen secretion from 
transfected myocytes (1) or by direct transfection of APCs (2).  Antigen can be released 
in apoptotic or necrotic bodies (3) or shed (4) and then can be taken up by APCs.  
APCs travel through an afferent lymphatic vessel (5) into a draining lymph node (6) 
where they process and present the antigen to T cells (7).  The activated antigen-
specific CD8+ T cells leave the draining lymph node via the efferent lymphatic vessel (8) 
and travel to the site of the tumor where they selectively kill antigen-bearing tumor 
cells.    
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Figure 2.  Structure of heat shock protein 70 (Hsp70).  Hsp70 consists of three 
major functional domains, an ATPase domain, a substrate-binding domain and a α-
helical domain. 
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Figure 3.  Immunostimulatory properties of heat shock proteins (From “Heat 
shock proteins as vaccine adjuvants in infections and cancer” (27)).  Heat shock 
proteins (Hsps) are potent adjuvants that can activate both the innate and adaptive 
immune systems following induction during physiological stress.  Hsps can activate 
APCs leading to their maturation and the production of immunostimulatory cytokines.  
Additionally, when bound with client proteins, Hsps can deliver these proteins to the 
APC.  These proteins are presented by MHC Class I to CD8+ T cells, leading to a 
CD8+ T cell response that is capable of killing tumor cells.  In addition, Hsps can 
activate natural killer (NK) cells which also have the ability to lyse tumor cells.   
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Chapter 2: 
Transdermal Delivery of Plasmid DNA Elicits Antigen-Specific CD8+ T cell 
Responses 
DNA vaccines encoding tumor antigens produce powerful anti-tumor immune 
responses in animal models, but clinical trials show only modest responses.  Although 
DNA plasmids have many advantages including low cost, ease of production, flexibility 
and safety, they also have disadvantages, including low transfection efficiency, transient 
protein expression and low immunogenicity.  These barriers must be overcome to 
increase the efficacy of plasmid DNA vaccines.  To this end, we produced a series of 
DNA plasmids designed to elicit antigen-specific CD8+ T cell responses.  The plasmids 
encoded the potent immune adjuvant heat shock protein 70 (Hsp70), a secretion sequence 
and several model antigens.  The plasmids were delivered transdermally using a tattoo 
device.  We found that the DNA plasmids led to protein production in vitro and in vivo 
and led to functional antigen-specific CD8+ T cell responses.  One immunization was as 
effective as multiple immunizations and the secretion sequence did not appear to enhance 
the resulting immune response.  These plasmids will serve as the foundation for future 
plasmid DNA-based vaccines. 
 
Introduction: 
Vaccines have been used to prevent bacterial and viral diseases for over a century, 
but only in the last 30 years have their potential for cancer treatment been explored.  This 
delay reflects the difficulties in producing potent immune responses against self-tumor 
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antigens and the immunosuppressive nature of cancer.  Over the past several decades, our 
understanding of tumor immunity has evolved to the point where the development of 
prophylactic and therapeutic cancer vaccines are now a reality (10)(42).     
Our goal is to produce vaccines that can elicit CD8+ T cell responses against 
tumor-associated and tumor-specific antigens.  CD8+ T cells recognize peptides presented 
on MHC Class I molecules, which include intracellular proteins produced in virus-
infected cells and tumor cells.  Activated CD8+ T cells differentiate into cytotoxic T cells 
that kill target cells by release of cytotoxins such as perforins, granzymes and granulysins 
and through cell contact via the Fas and TRAIL death pathways.  Therefore, CD8+ T cells 
play a critical role in anti-tumor immune responses.  Our long term goal is to optimize 
anti-tumor vaccines to produce potent and long-lived immune responses capable of 
rejecting spontaneous tumors and preventing tumor recurrence. 
This chapter describes our initial efforts to produce and characterize plasmid 
DNA (pDNA) vaccines.  pDNA vaccines have several advantages over protein/peptide 
vaccines including low cost, ease of production and manipulation, high stability and low 
toxicity (20-22).  DNA vaccines are typically administered intramuscularly or 
intradermally (15-18).  Following vaccination, resident cells (e.g. myocytes or 
keratinocytes) take up the plasmid and express the encoded antigen.  The antigen can 
then be presented to CD8+ T cells either directly by antigen presenting cells (APCs) that 
have been transfected with the plasmid or indirectly following the release of antigen from 
keratinocytes or myocytes and their subsequent uptake by and presentation on APCs.  
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The CD8+ T cells are activated, proliferate and migrate to the site of the tumor where 
they can specifically kill antigen-bearing target cells.   
We constructed a series of plasmids that all encoded the same three peptides:  two 
were derived from chicken ovalbumin (OVA) and the third was derived from the mouse 
MHC class II molecule, I-Eα.  All three epitopes were chosen due to the availability of 
mice bearing the transgenic T cell receptors (TCR) that recognize the peptides presented 
by H-2b molecules.  OT-I and OT-II mice bear TCRs that specifically recognize the OVA 
peptides 257-264 and 323-339 presented by Kb and I-Ab, respectively (43, 44).  TEa mice 
bear a TCR specific for the mouse I-Eα 52-68 peptide presented by I-Ab (45).  In 
addition, there are antibodies specific for the OT-I and I-Eα peptides presented by Kb and 
I-Ab, respectively (46, 47).  Collectively these peptides will enable us to track peptide 
presentation by APCs and antigen-specific T cell responses for both CD4+ and CD8+ T 
cells. 
In an effort to elicit a powerful immune response, the DNA vaccines included a 
gene encoding the adjuvant heat shock protein 70 (Hsp70).  Heat shock proteins (Hsps) 
are intracellular chaperones, some of which protect cells from chemical and physical 
stress (25, 26).  Several Hsps, including Hsp70, are also potent immunostimulants (29, 
32, 48, 49).  Following stress or necrotic cell death, Hsps and their client proteins are 
released from the cell and may be subsequently bound by receptors on APCs.  This can 
lead to the cross-presentation of client protein-derived peptides on MHC class I 
molecules and the activation of antigen-specific CD8+ T cells that mature into cytolytic 
  23 
effectors.  The net result is a protective CD8+ T cell response in animal models of viral 
and tumor immunity (28-32)(50). 
Finally, we chose to deliver the plasmid DNA to the skin instead of intramuscular 
injection.  The skin is a barrier organ relatively rich in APCs whereas the muscle has very 
few APCs.  Additionally, while both intradermal and intramuscular vaccination typically 
require three immunizations, they are spaced closer together and the resultant response is 
much quicker with intradermal immunization, typically in less than two weeks versus six 
weeks or more via the intramuscular route (37).   
The most common device used for intradermal immunization is the gene gun (34-
35).  A gene gun is a device that shoots gold coated particles into cells using a low 
pressure helium pulse.  This device was designed for transformation of plant cells, but is 
now commonly used for delivering genetic material to all types of cells. Nanogram 
amounts of DNA administered using a gene gun can elicit humoral and cytotoxic T 
lymphocyte responses (18).   
However, in 2005 Bins and colleagues described a new DNA vaccination method 
that employs a tattoo device for transdermal delivery (37).  They compared antigen-
specific T cell responses elicited by tattooing to responses obtained via intramuscular 
injection and intradermal administration via a gene gun.  The responses with tattooing 
were similar to that achieved with the gene gun, but a tattoo device is less expensive and 
easier to use.  Compared to intramuscular vaccination, intradermal administration via 
tattooing consistently activated higher frequencies of antigen-specific CD8+ T cells and it 
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did so in a shorter time.  Due to the advantages of using a tattoo device for DNA delivery, 
we chose this method for DNA immunization.  
We show that transfection with plasmid DNA results in protein production and 
secretion (with the encoded secretion sequence) and it elicits functional antigen-specific 
CD8+ T cell responses.  Furthermore, we show that addition of the secretion sequence 
does not enhance the resulting immune response and that one immunization results in an 
equivalent immune response to two or three immunizations.  Future work will include 
characterizing the CD4+ T cell response and antigen presentation by DCs following 
plasmid administration. 
 
Materials and Methods: 
DNA constructs. The plasmids were constructed in the pcDNA3.1(+) backbone 
(Invitrogen, Carlsbad, CA) which contains the cytomegalovirus (CMV) promoter for 
expression in mammalian cells.  A codon-optimized insert was synthesized (GenScript, 
Piscataway, NJ) to encode a Kozak consensus sequence, a signal sequence, a 10x 
histidine (His) tag and mouse heat shock protein 70 (Hsp70), and was inserted into the 
NheI and PmeI sites in pcDNA3.1(+).  The resultant plasmid was designated pWMD1S.  
A double stranded oligonucleotide with NheI and SwaI compatible 5’ and 3’ ends, 
respectively, was synthesized to encode the Kozak consensus sequence and a 10x His tag. 
This oligonucleotide was cloned into pWMD1S restricted with NheI and SwaI, thereby 
removing the signal sequence and creating pWMD1.  A cassette encoding green 
fluorescent protein (dGFP), a Gly4Ser linker, and three model peptides was codon-
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optimized for expression in mouse cells, synthesized (GenScript), and subcloned from a 
separate vector into pWMD1S and pWMD1 to form pWMD2S and pWMD2, 
respectively. 
All plasmids were transformed into Mach1 E. coli cells (Invitrogen).  
Transformed bacteria were grown in LB-broth (Invitrogen) supplemented with 
ampicillin.  Plasmids were isolated with the PureLink HiPure Filter Plasmid Purification 
Maxiprep kit (Invitrogen) according to the manufacturer’s instructions.  Following 
elution in water, the plasmids were concentrated to 4-6 µg/µl by ethanol precipitation, 
resuspended in water and stored at -20°C.  All constructs were sequence verified. 
 
Cell lines and transfections.  HEK293T cells (a gift from the Polunovsky lab at the 
University of Minnesota, Minneapolis, MN) were maintained in complete Dulbecco’s 
modified Eagle’s medium (Invitrogen) supplemented with 10% fetal bovine serum 
(Invitrogen) at 37°C with 5% CO2.  Adherent cells were dissociated from tissue culture 
flasks with TrypLE Express (Invitrogen) and plated in 6 well tissue culture-treated plates 
(BD Biosciences, San Jose, CA) at equal numbers (2-5 x 105 cells) per well without 
antibiotics.  The following day cells were transfected with 4 µg per well of pWMD2 or 
pWMD2S using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s 
protocol.  Cells were harvested 24 to 48 hours later for flow cytometry and Western blot 
analyses. 
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Western blot analysis. HEK293T cells were transfected with pWMD2 or pWMD2S and 
two days later the cells and supernatants were harvested.  The cells were lysed using 
RIPA lysis buffer (Millipore, Billerica, MA) and the proteins within the cell lysate (and 
supernatant) were purified over His SpinTrap columns from GE Healthcare (Piscataway, 
NJ) and eluted according to the manufacturer’s protocol.  The samples were denatured 
using sodium dodecyl sulfate (SDS), run on NuPAGE 4-12% Bis-Tris gradient gels 
(Invitrogen), transferred to Hybond-ECL nitrocellulose membranes (GE Healthcare) and 
probed using anti-His-HRP from AbD Serotec (Raleigh, NC).   
 
Flow cytometry analysis of 293T cells. HEK293T cells were transfected with pWMD2 or 
pWMD2S and 24 hours later the cells were harvested and analyzed for GFP expression 
by flow cytometry on a BD FACSCalibur flow cytometer (BD Biosciences) using BD 
CellQuest Pro software (BD Biosciences) and analyzed with FlowJo software (Tree Star, 
Inc., Ashland, OR). 
 
Mice.  Four to eight week old female C57BL/6 mice were purchased from the Jackson 
Laboratory (Bar Harbor, ME) or the National Cancer Institute (Frederick, MD). 
C57BL/6-Tg(TcraTcrb)1100Mjb/J (OT-I) Thy1.1+/Thy1.2+ mice were a generous gift 
from Dr. Stephen Jameson at the University of Minnesota (Minneapolis, MN). All mice 
were housed under specific pathogen free-conditions at the University of Minnesota 
(Minneapolis, MN).  All animal procedures were carried out according to protocols 
approved by the Institutional Animal Care and Use Committee. 
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OT-I adoptive cell transfer. All work was carried out under asceptic conditions using 
sterile reagents.  OT-I mice were euthanized and lymph nodes were harvested.  Single 
cell suspensions were prepared and cells were washed in phosphate buffered saline (PBS) 
supplemented with 2% (v/v) fetal bovine serum (Invitrogen).  Cells were counted and 
analyzed by flow cytometry to determine the percentage and number of OT-I cells. 
Antibodies used were CD44-FITC, B220-PE, and CD8α-APC (eBiosciences, San Diego, 
CA) and Thy1.1-PerCP (BD Pharmingen, San Diego, CA).  The OT-I phenotype was 
B220-CD8+Thy1.1+.  Additionally, the OT-I cells were CD44low, indicating they were 
naïve at the time of transfer.  To determine the cell count, PKH26 Reference Beads 
(Sigma-Aldrich, St. Louis, MO) were mixed with cells; 5,000 bead events were collected 
on the flow cytometer. The following equation was used to determine the number of 
lymphocytes: # cells/ml = (# cells acquired x dilution factor of cells x # singlet beads/ml) 
/ (# beads acquired x dilution factor beads).  Cell counts were verified manually using a 
hemocytometer. Data were acquired on a BD FACSCalibur flow cytometer (BD 
Biosciences) using BD CellQuest Pro software (BD Biosciences) and analyzed with 
FlowJo software (Tree Star, Inc.).  Cells were washed in PBS with 1% (v/v) fetal bovine 
serum and then in PBS before being resuspended at 107 cells/ml in PBS. 106 cells were 
transferred into each anesthetized mouse via retro-orbital injection using 1ml tuberculin 
syringes and 27 gauge needles.  
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DNA immunizations. Mice were anesthetized and their inner hind legs were shaved and 
wiped with 70% ethanol.  The mice were immunized with 40 µg of plasmid DNA in 10-
15 µl volumes on the indicated days.  The plasmids were delivered transdermally using a 
Cheyenne Hawk PU II tattoo device (Unimax Supply Co. Inc., New York, NY) set at 110 
Hz using 9-point needles.  The needle was adjusted to a depth of 0.5mm.  DNA was 
delivered over an area of approximately 1cm2 for 30 seconds. 
 
CD8+ T cell proliferation and function assays.  Mice were adoptively transferred with 106 
OT-I cells on -d1 and immunized with DNA using a tattoo device on d0, d3 and d6.  
Splenocytes and the draining inguinal lymph nodes were harvested on d12 and analyzed 
by flow cytometry for percentages of OT-I cells (B220-CD8+Thy1.1+).  Functionality was 
assessed by IFN-γ production following a brief exposure of cells to antigen in vitro.  
Splenocytes were incubated with or without 1µM SIINFEKL for 4 hours at 37°C and 
then examined for extracellular expression of CD8 and Thy1.1 (to identify OT-I cells) 
and intracellular expression of IFN-γ using BD Cytofix/Cytoperm kit (BD Biosciences).  
Data were acquired on a BD FACSCalibur flow cytometer (BD Biosciences) using BD 
CellQuest Pro software (BD Biosciences) and analyzed with FlowJo software (Tree Star, 
Inc.). 
 
Statistical analysis. All statistical analyses were performed by the unpaired two-tailed 
Student’s t-test unless noted otherwise. 
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Results: 
DNA plasmid construction: 
As a first step towards developing potent plasmid DNA-based cancer vaccines, 
we constructed a series of vectors encoding model antigens with and without a signal 
sequence for secretion.  The parental plasmid was pcDNA3.1(+), which contains the 
CMV promoter to drive expression in mammalian cells (Figure 1).  This plasmid is 
commonly used for DNA vaccines as the CMV promoter leads to high levels of protein 
production.  All of our constructs include a Kozak consensus sequence upstream of the 
start codon for optimal eukaryotic translation initiation.  Two constructs (pWMD1S and 
pWMD2S) include a signal sequence (called a secrecon) to permit protein secretion (51).  
A secretion sequence was included since the Haanen group found that ~99% of the cells 
transfected with a DNA plasmid using transdermal delivery were keratinocytes and only 
~1% of the transfected cells were Langerhans cells, a type of dendritic cell (78).  We 
reasoned that secretion by keratinocytes would permit more protein to be internalized and 
presented by APCs, leading to a more powerful immune response than if protein release 
by keratinocytes was solely due to cell death.  All plasmids were sequence verified (data 
not shown). 
The plasmids include two methods of detection, a 10X histidine (His) tag used 
both for detection and purification, and a modified green fluorescent protein (dGFP) for 
detection.  The 10X His tag and dGFP enable both easy purification and easy detection in 
vitro.  There are three peptides encoded in the plasmids: two are derived from chicken 
ovalbumin (OVA) and one from the mouse MHC class II molecule I-Eα.  In addition, 
Tattooing 
-d1 
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d0 d3 d6 d12 
d14 d28 
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murine Hsp70, a potent immune adjuvant, is fused to the carboxy terminus of the peptide 
cassette.  Hsp70 is a commonly used immune adjuvant that has been shown to produce 
potent CD8+ T cell responses (49)(52). 
 
Production and secretion of plasmid-encoded proteins: 
Following plasmid production and purification, HEK293T cells were transfected 
with pWMD2 or pWMD2S and both the cells and supernatant were harvested 48 hours 
later.  The proteins were purified from the cell lysate and supernatant using His-tag 
purification and Western blots were performed using His-tag detection antibodies (Figure 
2A).  The protein was produced but not secreted following transfection with pWMD2 
(which lacks the secretion sequence) as evidenced by an immunoreactive protein in the 
cell lysate sample but not in the supernatant.  An immunoreactive protein was detected in 
the supernatant, but not in the cell lysate, of HEK293T cells transfected with pWMD2S 
(which includes the secretion sequence).  The lack of a detectable immunoreactive 
protein in the cell lysate may be due to the rapid secretion of the protein.  We conclude 
the protein is expressed and that the His tag and signal sequence are functional. 
Next, HEK293T cells were transfected with either pWMD2 or pWMD2S and 
analyzed by flow cytometry 24 hours later.  As Figure 2B shows, about 8% of the 
pWMD2S-transfected cells were GFP+ whereas 29% of the pWMD2-transfected cells 
were GFP+.  We speculate that the lower percentage of GFP+ cells within the pWMD2S-
transfected cells is due to protein secretion.  We conclude the GFP within the protein is 
also functional as detected by fluorescence using flow cytometry.       
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Immunization strategy: 
 To detect the antigen-specific CD8+ T cell response following DNA plasmid 
administration, an OT-I adoptive transfer system was used (Figure 3).  The CD8+ T cells 
in OT-I mice bear a transgenic TCR specific for the SIINFEKL peptide (aa 257-264 in 
OVA) when presented by the MHC class I molecule H-2Kb (43).  This peptide is the 
CD8+ T cell epitope of OVA contained in the pWMD2 and pWMD2S plasmids.  OT-
I/PL mice express the OT-I TCR and the Thy1.1 allelic marker.  CD8+ OT-I (Thy1.1) 
cells adoptively transferred into C57BL/6 mice can be distinguished from host CD8+ T 
cells (Thy1.2) based on this allelic difference.   
C57BL/6 mice were adoptively transferred with 106 OT-I/PL cells one day prior 
(-d1) to immunization.  On d0, d3 and d6 the mice were immunized transdermally on the 
left hind leg with 40 µg plasmid DNA using a rotary tattoo device containing an 8-prong 
needle.  The DNA administration on d0, d3 and d6 was chosen based on optimization by 
the Hannen group (53).  On d12, the mice were sacrificed, the spleens harvested and 
antigen-specific OT-I cell responses were measured.     
 
Expansion of antigen-specific CD8+ T cells following immunization: 
Following validation that the plasmids produced protein and that the protein was 
secreted, we tested the immunogenicity of the plasmid-encoding OT-I epitope.  
Following adoptive transfer of equal numbers of OT-I cells on -d1, mice were immunized 
with either a control or pWMD2S on d0, d3 and d6.  On d12, splenocytes were harvested 
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and stained with fluorescently labeled antibodies for CD8, Thy1.1 and B220 (a marker 
used to exclude B cells).  The number of OT-I cells (CD8+Thy1.1+B220-) was quantitated 
by flow cytometry.  As seen in Figure 4, immunization with pWMD2S led to 
significantly greater numbers and percentages of antigen-specific CD8+ T cells than 
immunization with PBS or the vector control.  pWMD2S immunization resulted in a 
greater than 3.5 fold increase in OT-I cells compared to the controls, showing the 
immunogenicity of this vaccine.   
 
Effect of the secretion sequence on the resultant immune response and the functional 
ability of the activated CD8+ T cells: 
Because our goal is not only to establish a system in which to test DNA vaccines, 
but also to begin vaccine optimization, we next compared the plasmids with and without 
the secretion sequence.  C57BL/6 mice were adoptively transferred with equal numbers 
of OT-I cells on –d1 and immunized on d0, d3 and d6 with a control vector, pWMD2 or 
pWMD2S using a tattoo device.  On d12, OT-I cells were identified by their expression 
of CD8 and the allelic marker Thy1.1.  The proliferative responses of OT-I cells were 
similar in mice immunized with either pWMD2 or pWMD2S (~0.6% and ~0.7% of CD8+ 
T cells, respectively), with the percentage slightly higher for pWMD2S-immunized mice 
(Figure 5A).  We conclude that the secretion sequence does not have a significant effect 
on the resulting CD8+ T cell response.  
To assess their functionality, we briefly stimulated OT-I cells in vitro with their 
cognate antigen, SIINFEKL peptide presented by H-2Kb, and examined them for IFN-γ 
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expression (an effector cytokine) by intracellular staining followed by flow cytometry 
analysis.  The resultant antigen-specific CD8+ T cells are functional as shown by the 
significant increase in intracellular staining for IFN-γ following peptide stimulation 
(Figure 5B).   
 
Effect of the number of immunizations on the CD8+ T cell response: 
Finally, we asked if three immunizations were required for the optimal OT-I T 
cell response, as reported for endogenous CD8+ T cell responses elicited by plasmid 
DNA immunization via tattooing (53).  For this, we immunized mice one, two or three 
times and compared the resulting T cell responses.  C57BL/6 mice were adoptively 
transferred with equal numbers of OT-I cells on -d1 and immunized either once (on d0) 
or twice (on d0 and d3) with pWMD2S.  Six days after the last immunization, OT-I cells 
were identified by flow cytometry.  The proliferative responses of OT-I cells in mice 
immunized with one or two immunizations were similar (~0.45% and ~0.4% of CD8+ T 
cells, respectively) (Figure 6).  Additionally, this is not significantly different than the 
percentage of OT-I cells from three immunizations, suggesting that one immunization is 
sufficient. 
 
Discussion: 
 The goal of these studies was to establish a platform in which to optimize DNA 
vaccines for cancer therapy.  For this, we addressed both the plasmid DNA vaccine 
components and the route/strategy for administration of the vaccine.  These studies show 
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that the DNA plasmids encode functional proteins expressed both in vitro and in vivo.  
We validated functional expression of the His-tag via immobilized metal ion affinity 
chromatography and detection using a specific monoclonal antibody.  Inclusion of the 
signal sequence permitted expression of a secreted protein.  Finally, expression of 
plasmid-encoded GFP was detected by flow cytometry.  
We evaluated the immunogenicity of the plasmids by adoptively transferring 
congenically marked antigen-specific CD8+ T cells into C57BL/6 mice and tracking the 
cell expansion following immunization.  The frequency of antigen-specific CD8+ T cells 
following plasmid immunization increased significantly and these cells were functional 
as measured by their ability to produce IFN-γ following a brief antigen pulse in vitro.  
The secrecon signal led to the secretion of proteins in vitro, but there was no significant 
difference in the resulting CD8+ T cell response in vivo.  This suggests that secretion is 
not necessary.   
Recently, directly transfected langerin+ dermal DCs and dermal DCs have been 
shown to be responsible for CD8+ T cell activation following intradermal DNA 
administration, with langerin+ dermal DCs playing the primary role (54).  Consequently, 
proteins produced in transfected keratinocytes may not be necessary for the resulting 
CD8+ T cell response, making protein secretion unnecessary.   
Finally, we compared one, two and three immunizations and found that one 
immunization is sufficient for a significant OT-I T cell response.  The sufficiency of one 
immunization may be due to the increased frequency of precursor antigen-specific CD8+ 
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T cells as a result of the adoptive transfer.  Future work will include comparing the 
endogenous CD8+ T cell response following one or multiple immunizations.   
Following transdermal DNA administration using a tattoo device, 0.4% to 0.7% 
of the CD8+ T cells in the spleen were OT-I cells.  Bins and colleagues found that ~5% of 
the CD8+ T cells in the peripheral blood were specific for the influenza A nucleoprotein 
epitope (NP) at the peak of the response following DNA tattoo administration (53).  The 
lower percentage of resulting OT-I cells than NP-specific CD8+ T cells may be due to 
differences in immunogenicity of the encoded proteins, differences in the adjuvants used, 
differences in the plasmids or differences in the kinetics of the responses.          
We chose to use the OT-I adoptive transfer system versus tracking endogenous 
responses since we have previous experience with this system and the reagents were 
readily available.  Future work will include tracking endogenous responses to OVA, 
examining responses to the OT-II and I-Eα epitopes encoded in the plasmids and using 
tumor models to examine the resulting anti-tumor response.  The OT-II epitope will be 
used to examine the CD4+ T cell response to DNA vaccination.  Both the OT-I epitope 
and I-Eα epitopes will be used to determine antigen presentation by DCs following 
transdermal delivery of the pDNA.  Additionally, OVA-expressing tumors can be used to 
examine the anti-tumor immune response following DNA vaccination.   
     In conclusion, the plasmids were made successfully and immunization via a 
tattoo device resulted in functional antigen-specific CD8+ T cell responses.  This DNA 
vaccine platform is now ready to be used for vaccine optimization.  Future directions for 
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this work include the optimization of DNA vaccines by overcoming transient protein 
expression (Chapter 3) and by increasing transfection efficiency (Chapter 4).    
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Figure 1.  pWMD plasmid constructs.  We produced the pWMD series of plasmids in 
pcDNA3.1(+) which contains the CMV promoter. Kozak – sequence for eukaryotic 
translation initiation; SS – secrecon signal sequence for secretion; 10xHis – detection 
tag; dGFP – detection; Linker – flexible linker; Antigen – encodes OT-I and OT-II 
epitopes of ovalbumin and mouse I-Ea derived peptides; Mhsp70 – murine Hsp70: an 
adjuvant.  A. Cloning strategy and representation of plasmid inserts.  B. Sequences of 
vaccine components.  C. Diagram of pWMD2S.  D. Nucleotide sequence of insert in 
pWMD2S (cloned in between the NheI/PmeI sites in pcDNA3.1+). 
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pWMD1S: The Kozak/SS/Tag/Adjuvant insert was codon optimized by GenScript for 
expression in mouse cells and inserted into the NheI/PmeI sites contained within 
pcDNA3.1(+). 
pWMD2S: The Color/Linker/Antigen cassette was codon optimized by GenScript for 
expression in mouse cells and was subcloned from a separate vector into pWMD1S as 
an EcoRI fragment. 
pWMD1:  A double stranded oligonucleotide with NheI and SwaI compatible 5’ and 3’ 
ends, respectively, was synthesized to encode the Kozak consensus sequence and a 
10xHis tag. This oligonucleotide was cloned into pWMD1S restricted with NheI and 
SwaI, thereby removing the secrecon signal sequence. 
pWMD2:  The Color/Linker/Antigen cassette was codon optimized by GenScript for 
expression in mouse cells and was subcloned from a separate vector into pWMD1 as an 
EcoRI fragment. 
A. 
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B. 
Kozak: gccgccaccatg 
 
Secrecon (51) : MWWRLWWLLLLLLLLWPMVWA   
 
dGFP:  
MSKGEELFTGVVPVLVELDGDVNGQKFSVSGEGEGDATYGKLTLNFICTTGKLP
VPWPTLVTTFSYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFYKDDGNYK
TRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKMEYNYNSHNVYIMGDKPKNGI
KVNFKIRHNIKDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKR
DHMILLEFVTAARITHGMDELYK 
 
OVA epitopes: (OT-I = OVA257-264; OT-II = OVA323-339) epitopes in bold face.  
Other residues are naturally occurring flanking amino acids included to facilitate antigen 
processing. 
GLEQLESIINFEKLTEWTSSSSAESLKISQAVHAAHAEINEAGREVVGSAE  
 
 
Ea epitope: EEFAKFASFEAQGALANIAVDKANLDVME 
 
Mhsp70: M A K N T A I G I D L G T T Y S C V G V F Q H G K V E I I A N D Q G N 
R T T P S Y V A F T D T E R L I G D A A K N Q V A L N P Q N T V F D A K R L I 
G R K F G D A V V Q S D M K H W P F Q V V N D G D K P K V Q V N Y K G E S 
R S F F P E E I S S M V L T K M K E I A E A Y L G H P V T N A V I T V P A Y F N 
D S Q R Q A T K D A G V I A G L N V L R I I N E P T A A A I A Y G L D R T G K 
G E R N V L I F D L G G G T F D V S I L T I D D G I F E V K A T A G D T H L G G 
E D F D N R L V S H F V E E F K R K H K K D I S Q N K R A V R R L R T A C E R 
A K R T L S S S T Q A S L E I D S L F E G I D F Y T S I T R A R F E E L C S D L F 
R G T L E P V E K A L R D A K M D K A Q I H D L V L V G G S T R I P K V Q K L 
L Q D F F N G R D L N K S I N P D E A V A Y G A A V Q A A I L M G D K S E N V 
Q D L L L L D V A P L S L G L E T A G G V M T A L I K R N S T I P T K Q T Q T F 
T T Y S D N Q P G V L I Q V Y E G E R A M T R D N N L L G R F E L S G I P P A P 
R G V P Q I E V T F D I D A N G I L N V T A T D K S T G K A N K I T I T N D K G 
R L S K E E I E R M V Q E A E R Y K A E D E V Q R D R V A A K N A L E S Y A F 
N M K S A V E D E G L K G K L S E A D K K K V L D K C Q E V I S W L D S N T 
L A D K E E F V H K R E E L E R V C S P I I S G L Y Q G A G A P G A G G F G A 
Q A P P K G A S G S G P T I E E V D 
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C. 
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gctagcgccgccaccatgtggtggcggctctggtggcttcttttgctgctcctgcttctgtggcccatggtgtgggcac
accatcaccatcaccatcatcaccaccatttaaatgaattctgtacaatgaagggggtgaaggaagtaatgaagatca
gtctggagatggactgcactgttaacggcgacaaatttaagatcactggggatggaacaggagaaccttacgaagga
acacagactttacatcttacagagaaggaaggcaagcctctgacgttttctttcgatgtattgacaccagcatttcagtat
ggaaaccgtacattcaccaaatacccaggcaatataccagactttttcaagcagaccgtttctggtggcgggtatacct
gggagcgaaaaatgacttatgaagacgggggcataagtaacgtccgaagcgacatcagtgtgaaaggtgactctttc
tactataagattcacttcactggcgagtttcctcctcatggtccagtgatgcagaggaagacagtaaaatgggagccat
ccactgaagtaatgtatgttgacgacaagagtgacggtgtgctgaagggagatgtcaacatggctctgttgcttaaag
atggccgccatttgagagttgactttaacacttcttacatacccaagaagaaggtcgagaatatgcctgactaccatttta
tagaccaccgcattgagattctgggcaacccagaagacaagccggtcaagctgtacgagtgtgctgtagctcgctatt
ctctgctgcctgagaagaacaagtgtacatccggaggaggaggaagcggaggaggaggcagcggaggaggag
gatccggagatatcctgaggggcctggagcagctggagtcgatcatcaacttcgagaagttgaccgagtggacctc
ctccagcagcgccgagagcctgaagattagccaggccgtgcacgccgcccacgctgagattaacgaggccggcc
gcgaggtggtgggaagtgctgagtccctgaggcacgtggaggagtttgccaagttcgcctccttcgaggcccaggg
cgccctggccaacatcgccgtggataaggccaacctggatgtgatggagcacgtggaattcttaattaatatggccaa
gaacactgctattggcatagatctgggaactacatattcttgcgtgggcgtctttcaacacggaaaggtcgagattatcg
ccaacgatcagggtaatcgaacaacacctagctacgtcgcattcaccgacacagagcgtctcatcggagacgcagc
caagaaccaggtggccctcaatccccagaatacagtgtttgatgccaagcgcctcatcgggcgcaagtttggagatg
ctgtggttcagtcagacatgaagcattggcccttccaagtggtgaacgatggcgacaaaccaaaggtccaggtcaac
tacaaaggcgagtctcggagcttcttccccgaggaaattagcagcatggtgctcacaaagatgaaggagatagccg
aagcttatttgggccatcccgtcaccaacgcagtgatcaccgtgcctgcctattttaacgattcccaaagacaggctact
aaggatgccggcgtgatcgccggactcaacgtgctgagaatcatcaacgagcctacagccgccgccatcgcctac
ggattggaccggacagggaaaggcgagcgtaatgtcctgatattcgacctcggaggtgggactttcgatgtcagcat
cctcactatagacgatggaatttttgaggtgaaggccaccgctggggatactcatctgggaggcgaggacttcgataa
cagactggtcagtcatttcgtcgaggagttcaagcgaaaacacaaaaaagacatcagtcaaaacaaacgcgccgtc
cggcgtctgcgcaccgcctgtgagagggctaagagaaccctgagcagttccacccaggcaagccttgaaatcgata
gtctgtttgagggcatcgacttctatacatccataacaagggctcgattcgaggagctgtgtagcgacctgttcagggg
aacactggaaccagtggagaaggccctgagagacgccaaaatggacaaggctcagattcacgacctggtcctggt
gggcggaagtactcggatccccaaggtgcagaagctccttcaggatttcttcaacggacgcgacctcaacaagtcta
tcaatcctgatgaggccgtggcatacggcgcagccgtgcaagcagcaatactcatgggagacaagagcgagaacg
tgcaggacctgctgctgctggatgtggcccccctgtcactcggactcgaaacagccgggggcgtgatgactgccct
gatcaagcgaaattctaccattccgaccaagcagactcagacattcacaacctactcagataaccagccaggcgtgct
gatccaggtgtacgaaggagagagagcaatgactagggacaacaacctgctgggcagattcgagctctccggcat
ccctccagctcctcggggagttcctcagattgaggtgacttttgacatcgacgcaaacggtattttgaacgttaccgcta
ccgataagtctaccggcaaggccaacaaaattaccataactaatgataaggggcggttgagtaaggaggagatcga
gcgaatggtgcaggaagctgagagatacaaggctgaggatgaggtccagcgcgaccgggtggcagccaagaac
gccctcgaatcatatgcctttaacatgaaatcagctgtggaagatgaaggcctgaaagggaagctctccgaggccga
taagaaaaaggtgctggataagtgtcaggaagtgattagttggttggatagcaataccctggccgataaggaggaatt
tgtgcacaagagggaggaactcgagagagtctgcagtcccatcatcagtgggctctatcagggtgctggcgctccc
ggggccggaggcttcggggcccaagctccccccaaaggtgcctccggctccgggccaaccatcgaggaggtgg
attgattaattaactgatctaga 
 
D. 
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Figure 2.  Protein expression and secretion in 293T cells. HEK293T cells were 
transfected with pWMD2 or pWMD2S and the cells and supernatant were harvested 
either 24 (B) or 48 (A) hours later.  A. Western blot using anti-His-HRP 48 hours after 
transfection.  Proteins were first purified by means of the His tag.  Lane 1: Cells 
transfected with pWMD2.  Lane 2: Supernatant from cells transfected with pWMD2.  
Lane 3: Cells transfected with pWMD2S.  Lane 4: Supernatant from cells transfected 
with pWMD2S.  B. Flow cytometry contour plots of control cells or cells transfected 
with pWMD2 or pWMD2S 24 hours prior to analysis (expression of GFP-containing 
proteins).      
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Figure 3.  DNA tattooing procedure. C57BL/6 (Thy1.2) mice were adoptively 
transferred with 106 allelically marked (Thy1.1) OT-I cells one day prior (-d1) to 
immunization. Mice were then immunized intradermally on the left hind leg with a 
rotary tattoo device for 16 seconds with 40 µg DNA on the indicated days. Readouts 
were the numbers and percentages of OT-I cells (CD8+Thy1.1+) as measured by flow 
cytometry on d12. 
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Figure 4.  Antigen specific CD8+ T cell response to pWMD2S following DNA 
tattooing. C57BL/6 (Thy1.2) mice were adoptively transferred with 106 OT-I cells 
one day prior to immunization. The mice were then immunized intradermally on the 
left hind leg using a tattoo device with 40µg DNA on d0, d3 and d6.  A. Dot plots of 
OT-I cells (CD8+Thy1.1+) as measured by flow cytometry on d12.  B-C. Percentage 
and number of OT-I cells of total splenocytes measured by flow cytometry on d12. 
***P=<.001 TTEST, 1 Tail, Type 2. 
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Figure 5.  Functional antigen specific CD8+ T cell response with and without the 
secretion sequence. C57BL/6 (Thy1.2) mice were adoptively transferred with 106 OT-I 
cells one day prior to immunization. The mice were then immunized intradermally on 
the left hind leg using a tattoo device with 40µg DNA on d0, d3 and d6.  A. Percentage 
of OT-I cells (CD8+Thy1.1+) as measured by flow cytometry as percentage of CD8+ T 
cells on d12.  B. Percentage of IFN-γ+ OT-I cells following ex vivo peptide stimulation 
on d12. *P=<.05 (pWMD2 P=0.022, pWMD2S P=0.029) TTEST 1 Tail, Type 2. 
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Figure 6.  Antigen specific CD8+ T cell response following one, two or three 
immunizations. C57BL/6 (Thy1.2) mice were adoptively transferred with 106 OT-I 
cells one day prior to immunization. The mice were then immunized intradermally on 
the left hind leg using a tattoo device with 40µg DNA either on d0, on d0 and d3, or 
on d0, d3 and d6.  Splenocytes were harvested 6 days after the last immunization.  
Percentage of OT-I cells (CD8+Thy1.1+) as measured by flow cytometry (as 
percentage of CD8+ T cells).  *P=<.05 (pWMD2 P=0.022, pWMD2S P=0.029) 
TTEST 1 Tail, Type 2. 
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Plasmid DNA-based gene delivery in mammals can result in brief transgene 
expression. This is most likely due to the spread of transcriptionally repressive chromatin 
initially deposited on plasmid bacterial backbone sequences.  Minicircle DNA lacks 
plasmid backbone sequences and correspondingly, confers higher levels of relatively 
durable transgene expression upon gene delivery. In this study we show minicircle DNA 
also elicits enhanced antigen-specific CD8+ T cell responses in vivo. We first used a 
luciferase reporter transgene to demonstrate that transdermal delivery of minicircle DNA, 
as compared to full-length plasmid DNA, resulted in significantly higher and persistent 
levels of luciferase expression in the skin. Minicircle DNA encoding an epitope 
recognized by CD8+ T cells similarly elicited more potent and durable specific immune 
responses than the corresponding full-length plasmid DNA. Together our results suggest 
transdermal delivery of minicircle DNA vaccines may prove to be more efficacious for 
prophylaxis and therapy than traditional plasmid DNA vaccines. 
  54 
Introduction: 
Minicircle (MC) DNA is potentially superior to plasmid DNA (pDNA) as a 
nonviral vector for gene delivery (55, 56). Although both vector types contain expression 
cassettes that permit transgene products to be made at high levels shortly after delivery in 
vivo, expression rapidly wanes following delivery with standard full-length (FL) pDNA 
vectors because transcriptionally repressive heterochromatin is deposited on the plasmid 
bacterial backbone (57, 58). Heterochromatin then spreads in cis to silence transgene 
expression, independent of CpG content and methylation status (59-61).  In contrast to 
pDNA, MC-encoded transgenes avoid this fate because MCs are devoid of essentially all 
prokaryotic sequence elements (e.g. origin of replication and antibiotic-resistance genes). 
Removal of these plasmid backbone sequences is achieved via site-specific 
recombination in Escherichia coli prior to episomal DNA isolation (62-64). The lack of 
these prokaryotic sequence elements also reduces MC size relative to its parental FL 
pDNA, leading to enhanced transfection efficiencies (65). The net result is that compared 
to their FL pDNA counterparts, MCs transfect a higher frequency of cells and permit 
durable high level transgene expression upon delivery in vivo.  
In vivo gene delivery has broad appeal because of its potential as a therapeutic 
agent that mediates long-term gene expression. While MC-based vectors have been 
employed for gene therapy (66, 67), to our knowledge they have not been tested for their 
potential in DNA vaccine therapy. pDNA vaccines enjoy several advantages over protein 
and viral vaccine-based strategies including low cost, ease of production, flexibility in 
design and fewer safety concerns (68-70). While pDNA vaccines encoding pathogen or 
  55 
tumor antigens (Ags) elicit immunity against infections or tumors in optimized animal 
models, clinical trials show only modest responses (71). These disappointing results 
likely are influenced by transient protein expression and low efficiency of gene delivery 
in vivo characteristic of FL pDNA. Because MC DNA does not have these limitations, we 
reasoned immune responses elicited by MC vaccines would be more potent than 
responses to FL pDNA vaccines encoding the Ags. 
The two main routes for administering DNA vaccines are intramuscular and 
intradermal. The intradermal route is preferred because the skin is a barrier organ 
relatively rich in cells that present Ag to the immune system (72, 73). Intradermal 
delivery methods for DNA include injection with a hypodermic needle, bombardment of 
the skin with DNA-coated gold particles ejected from a gene gun, topical application, 
electroporation and tattooing (74-78). Tattooing has the advantage of being relatively 
inexpensive and rapid, and the infliction of thousands of perforations likely serves as a 
potent adjuvant. We therefore used tattooing to deliver FL pDNA and their derivative 
MC vaccines transdermally to mice. We found that the level, duration and 
immunogenicity of the MC transgene-encoded proteins were all significantly greater than 
those elicited by the FL pDNA vaccines. We discuss these results relative to future 
strategies involving DNA-based vaccines. 
 
Materials and Methods: 
 
DNA constructs. The plasmid backbone for the FL constructs (pMC.BESPX) contains the 
requisite sequences for bacterial propagation (e.g. the pUC origin of replication), the 
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øC31 integrase recognition sites attB and attP, and a block of 32 tandem repeats of the 
recognition sequence for the I-SceI homing endonuclease (64).   
To generate the FL-eff construct, eff was amplified from the pUltra Bright eff 
luciferase+ plasmid (79) and inserted into a vector containing the bovine growth hormone 
polyadenylation signal (BpA).  The luciferase-BpA fragment was then PCR amplified. In 
a parallel PCR reaction the hUbC promoter (a generous gift from Michael Kyba, 
University of Minnesota, Minneapolis, MN) was amplified. The hUbC amplicon contains 
a 5’ overlap region with the pMC.BESPX plasmid upstream of the EcoRI site and an 
overlapping region with the eff 5’ sequence.  The luciferase/BpA amplicon contains an 
overlap region with the pMC.BESPX plasmid downstream of the EcoRV site.  The two 
PCR products and the EcoRI/EcoRV digested pMC.BESPX were subjected to a one-step 
isothermal DNA assembly protocol (80) allowing for seamless joining of the overlapping 
fragments.  
A similar strategy was utilized to generate the FL-Ag construct containing the 
hUbC promoter-driven Ag cassette.  The cassette encodes a signal sequence, a 10x 
histidine tag, a linker and a region that includes the chicken ovalbumin-derived peptide 
SIINFEKL (Supplementary Figure 1). It was amplified from a codon-optimized 
synthetic gene (GenScript, Piscataway, NJ) and inserted upstream of BpA. Overlapping 
PCR products for cloning hUbC-antigen-BpA were generated and isothermally 
assembled into pMC.BESPX. Sequences of all amplifying primers are available upon 
request from the authors. 
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All PCR reactions were performed using Phusion® High-Fidelity DNA 
Polymerase (New England BioLabs, Ipswich, MA) under the following conditions: 98°C 
x 30 seconds, followed by 35 cycles of 98°C x 10 seconds, 60°C x 30 seconds and 72°C 
x 120 seconds.  Plasmids containing the eff or Ag cassettes were then transformed into 
the ZYCY10P3S2T bacterial strain. ZYCY10P3S2T bears ten copies of the øC31 
integrase gene, three copies of the I-Sce1 homing endonuclease gene, and the araC.BAD 
promoter-controlled araE and LacY arabinose transporter genes that induce øC31 
integrase and I-Sce1 endonuclease expression (64). For FL pDNA preparation, 
transformed bacteria were grown in LB-broth (Invitrogen, Carlsbad, CA) supplemented 
with kanamycin. pDNA was by isolation using the PureLink HiPure Filter Plasmid 
Purification Maxiprep kit (Invitrogen) according to the manufacturer’s instructions.  For 
MC generation, bacteria transformed with FL pDNA were grown overnight in Terrific 
Broth supplemented with kanamycin (Invitrogen).  The following day MC induction 
media (fresh LB broth containing 0.04 volumes of 1N NaOH and 0.02% L-arabinose 
(Sigma-Aldrich, St Louis, MO)) were added and the culture temperature was decreased 
from 37˚C to 32˚C for 5-8 hours.  The culture was centrifuged and MC DNA was 
purified with the PureLink HiPure Filter Plasmid Purification Maxiprep kit (Invitrogen) 
by increasing the recommended volumes of buffers six-fold and using four columns. 
Following elution in water, the DNA was concentrated to 4-6 µg/µl by ethanol 
precipitation, resuspended in water and stored at -20°C. Sequence analyses verified the 
genes encoded by the FL pDNAs and their derivative MCs were identical.   
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Cell lines and transfections. COS cells were maintained in complete Dulbecco’s modified 
Eagle’s medium (Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen) and 
DC2.4 cells were maintained in complete RPMI 1640 (Invitrogen) supplemented with 
10% fetal bovine serum at 37°C with 5% CO2. Adherent cells were dissociated from 
tissue culture flasks with TrypLE Express (Invitrogen) and plated in 6 well tissue culture-
treated plates (BD Biosciences, San Jose, CA) at equal numbers (2-5 x 105 cells) per well 
without antibiotics.  The following day, cells were transfected using Lipofectamine LTX 
with PLUS Reagent (Invitrogen) according to the manufacturer’s protocol. COS cells 
were transfected with 2.5 µg (1.1 pmol) per well of MC-eff or equal molar amounts of 
VC or FL-eFF and were harvested two days later for flow cytometry analysis. DC2.4 
cells were transfected with 2.6 µg (1.8 pmol) of MC-Ag per well or equal molar amounts 
of VC or FL-Ag and were harvested one, three and five days later for flow cytometry 
analysis.  
 
Measurements of eff and Ag expression by flow cytometry. Staining for intracellular eff 
luciferase in COS cells was carried out using the BD Cytofix/Cytoperm kit (BD 
Biosciences) according to the manufacturer’s protocol. Fixed and permeabilized cells 
were incubated with an anti-luciferase-FITC conjugate (Lifespan Biosciences, Seattle, 
WA) for 20 minutes.  The DC2.4 cells were analyzed for cell surface antigen presentation 
using a 25-D1.16-APC conjugate (eBioscience, San Diego). 25-D1.16 is an antibody 
specific for the SIINFEKL/H-2Kb complex (46). Cells were stained at 4°C for 30 
minutes. Data were acquired on a BD FACSCalibur flow cytometer (BD Biosciences) 
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using BD CellQuest Pro software (BD Biosciences) and analyzed with FlowJo software 
(Tree Star, Inc., Ashland, OR).   
 
Mice.  Four to eight week old female C57BL/6 mice were purchased from the Jackson 
Laboratory (Bar Harbor, ME) or the National Cancer Institute (Frederick, MD). 
C57BL/6-Tg(TcraTcrb)1100Mjb/J (OT-I) Thy1.1+/Thy1.2+ mice were a generous gift 
from Dr. Stephen Jameson at the University of Minnesota (Minneapolis, MN). All mice 
were housed under specific pathogen free-conditions at the University of Minnesota 
(Minneapolis).  All animal procedures were carried out according to protocols approved 
by the Institutional Animal Care and Use Committee. 
 
OT-I adoptive cell transfer. All work was carried out under asceptic conditions using 
sterile reagents.  OT-I mice were euthanized and lymph nodes were harvested.  Single 
cell suspensions were prepared and cells were washed in phosphate buffered saline (PBS) 
supplemented with 2% (v/v) fetal bovine serum (Invitrogen). Cells were counted and 
analyzed by flow cytometry to determine the percentage and number of OT-I cells with 
the following antibody-fluorochrome conjugates: CD44-FITC, B220-PE, and CD8-APC 
(eBioscience) and Thy1.1-PerCP (BD Pharmingen, San Diego, CA). The OT-I phenotype 
was B220-CD8+Thy1.1+.  Additionally, the OT-I cells were CD44low, indicating they 
were naïve at the time of transfer.  To determine the cell count, PKH26 Reference Beads 
(Sigma-Aldrich) were mixed with cells; 5,000 bead events were collected on the flow 
cytometer. The following equation was used to determine the number of lymphocytes: # 
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cells/ml = (# cells acquired x dilution factor of cells x # singlet beads/ml) / (# beads 
acquired x dilution factor beads).  Cell counts were verified manually using a 
hemocytometer. Data were acquired on a BD FACSCalibur flow cytometer (BD 
Biosciences) using BD CellQuest Pro software (BD Biosciences) and analyzed with 
FlowJo software (Tree Star, Inc.).  Cells were washed in PBS with 1% (v/v) fetal bovine 
serum and then in PBS before being resuspended at 106 cells/ml in PBS. 105 cells were 
transferred into each anesthetized mouse via retro-orbital injection using 1 ml tuberculin 
syringes and 27 gauge needles.  
 
DNA immunizations. Mice were anesthetized and their inner hind legs were shaved and 
sterilized with 70% ethanol. Based on pilot experiments, mice were immunized with 20 
µg of MC DNA in 10-15 µl volumes. This mass converts to 9.2 and 13.9 pmol for MC-
eff and MC-Ag, respectively. Equimolar amounts of VC and the corresponding FL 
pDNA samples were diluted in sterile water to the same volumes. All DNA was delivered 
transdermally over an area of approximately 1 cm2 for 30 seconds using a Cheyenne 
Hawk PU II tattoo device (Unimax Supply Co. Inc., New York, NY) set at 110 Hz using 
9-point needles adjusted to a depth of 0.5 mm.   
 
Bioluminescence measured in vivo.  Mice were imaged for bioluminescence using a 
Xenogen IVIS Imaging System (Caliper Life Sciences, Hopkinton, MA). Data were 
analyzed using Living Image 2.5 Software (Caliper Life Sciences).  Briefly, mice were 
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injected intraperitoneally with 100 µl of 30 mg/ml luciferin and anesthetized with 
isoflurane. Bioluminescence was measured for 5 minutes.   
 
CD8+ T cell proliferation and function assays.  Mice were adoptively transferred with 105 
OT-I cells and the next day immunized with DNA using a tattoo device as described 
above. Splenocytes and the draining inguinal lymph nodes were harvested seven days 
later and analyzed by flow cytometry for percentages of OT-I cells. Functionality was 
assessed by IFN-γ production following a brief exposure of cells to antigen in vitro. 
Splenocytes were incubated with or without 1 µM SIINFEKL for 4 hours at 37°C and 
then examined for extracellular expression of CD8 and Thy1.1 (to identify OT-I cells) 
and intracellular expression of IFN-γ using BD Cytofix/Cytoperm kit (BD Biosciences). 
Data were acquired on a BD FACSCalibur flow cytometer (BD Biosciences) using BD 
CellQuest Pro software (BD Biosciences) and analyzed with FlowJo software (Tree Star, 
Inc.). 
 
In vivo cytotoxicity.  C57BL/6 mice were adoptively transferred with 106 OT-I cells and 
were immunized the next day with equimolar amounts of DNA using the tattoo device as 
described above.  Eight days later these mice were adoptively transferred with equal 
numbers (107 each) of syngeneic splenocytes that had been pulsed or not with SIINFEKL 
peptide (1 µg peptide per 2.5 x 107 cells for one hour at 37˚C). To distinguish the cells 
from one another and from host cells, peptide-pulsed and unpulsed splenocytes were 
respectively labeled with 5 µM 5-(and-6)-carboxyfluorescein diacetate, succinimidyl 
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ester (CFSE) and 0.5 µM CFSE. Fourteen hours later, the mice were euthanized and their 
splenocytes harvested and analyzed by flow cytometry for percentages of CFSEhigh 
(peptide pulsed) and CFSElow (unpulsed control) cells.  The percent specific killing was 
determined using the following formula: [1-(ratio in VC-immunized mouse/ratio in FL-
Ag or MC-Ag-immunized mouse)] X 100 (81).  
 
Statistical analysis.  All statistical analyses were performed by the unpaired two-tailed 
Student’s t-test unless noted otherwise. 
 
Results: 
 
Efficient production of MC-based expression vectors: 
We constructed two series of expression vectors. One encoded enhanced firefly 
(eff) luciferase as a reporter to track expression. The other encoded a model peptide to 
monitor specific T cell responses. We chose eff luciferase as a reporter because of its 
sensitivity; mouse cells expressing eff luciferase emit >100 times more light than cells 
expressing standard firefly luciferase (79). The model peptide was the chicken 
ovalbumin-derived peptide SIINFEKL. When the SIINFEKL peptide is bound by the 
mouse major histocompatibility class I molecule H-2Kb, it forms an Ag recognized by 
mouse CD8+ T cells bearing the Vα2/Vβ5 OT-I transgenic T cell receptor (43). Ag-
specific OT-I responses are easily tracked after these cells are adoptively transferred into 
C57BL/6 (H-2b) recipients who are subsequently immunized with chicken ovalbumin or 
the SIINFEKL peptide plus adjuvant (82). Expression of the eff and Ag genes was 
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controlled by the human ubiquitin C (hUbC) promoter, chosen because it efficiently 
drives transgene expression in many mouse tissues including skin (83).  
MC constructs encoding eff or Ag (MC-eff and MC-Ag, respectively) were 
generated from FL pDNA precursors (Fig. 1a). Briefly, we cloned the hUbC-driven 
expression cassettes between the øC31 integrase recognition sites attB and attP contained 
within the minicircle producer plasmid backbone (64). Upstream of the attP site was a 
block of 32 tandem repeats of the I-SceI homing endonuclease recognition sequence (83). 
FL pDNA was transformed into an E. coli strain (ZYCY10P3S2T) engineered to 
inducibly express øC31 integrase and I-SceI endonuclease (64). Upon induction, øC31 
integrase activity generated the MC and circular plasmid backbone; the latter was 
subsequently degraded by host bacterial exonucleases following linearization by the I-
SceI endonuclease. Densitometry analyses of ethidium bromide-stained agarose gels 
revealed that less than 5% of FL-eff pDNA remained in the purified MC-eff preparations 
(Fig. 1b). MC-Ag preparations were comparably pure (data not shown). 
 
Enhanced expression of MC-encoded eff luciferase in vitro: 
To determine if the expression levels or transfection efficiencies of MC-encoded 
genes were enhanced as compared to FL plasmid-encoded genes, we transfected COS 
cells transiently with equimolar amounts of MC-eff or FL-eff DNA.  Two days later the 
cells were analyzed by flow cytometry for intracellular luciferase expression (Fig. 2a).  
On average about 14% of cells transfected with MC-eFF expressed luciferase, more than 
twice the frequency (6%) of luciferase-expressing cells transfected with an equimolar 
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amount of FL-eff (Fig. 2b). However, the median fluorescent intensities of the two 
luciferase-expressing populations were comparable (P=0.65). Together these data suggest 
that under the conditions used, the smaller MC-eff (3348 bp) transfected COS cells more 
efficiently than the larger FL-eff (7262 bp). On a per cell basis, though, cells transfected 
with either construct expressed equivalent levels of eff luciferase two days post-
transfection. 
 
Enhanced expression of MC-encoded eff luciferase in skin: 
Because our goal is to develop MC-based vaccines, we next determined the 
intensity and duration of MC gene expression in vivo. We immunized mice intradermally 
since the skin is a barrier organ relatively rich in immune sentinel cells. Epidermal cells 
(e.g. keratinocytes) are critical for maintaining the immunological barrier function of the 
skin by initiating inflammation via recognition of damage- and pathogen-associated 
molecular patterns by pattern recognition receptors (84).  Dermal dendritic cells similarly 
initiate proinflammatory responses but they also can internalize and present antigen to B 
and T cells (72). Work by the Haanen group demonstrated pDNA delivery to the skin via 
tattooing elicited more rapid and robust immune responses specific for the pDNA-
encoded antigens than did intramuscular delivery (37). Therefore we tattooed the skin of 
mice with MC or FL DNA initially to compare the intensity and duration of gene 
expression, and later the immunogenicity of the proteins they encode. 
Each mouse in the experimental cohort was tattooed on the left and right thighs 
with equimolar amounts of FL-eff and MC-eff DNA, respectively. Mice in a separate 
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cohort were tattooed with equimolar amounts of FL pDNA lacking an expression cassette 
(empty vector control, VC). The mice were then injected with saturating amounts of 
luciferin substrate on the indicated days and imaged for bioluminescence (Fig. 3a). 
Consistent with previous reports of standard firefly luciferase expression resulting from 
pDNA tattooing (37), expression peaked two to three days post-delivery in both groups 
(Fig. 3b). However, luciferase activity encoded by MC-eff was consistently and 
significantly higher than that of FL-eff. Luciferase activity decayed to background levels 
by day 42 in the FL-eff cohort but it remained detectable in the MC-eff cohort throughout 
the 63-day observation period. It is noteworthy that the MC-eff luciferase activity on day 
63 was comparable to the FL-eff peak response on day 3. It took 49 days for luciferase 
activity in MC-eff mice to decay back to the levels measured on day 1 (P = 0.23; paired 
two-tailed t test). Together these data indicate that luciferase expression in the skin 
persists significantly longer and at significantly higher levels in mice tattooed with MC-
eff relative to FL-eff. 
 
Enhanced presentation of MC-encoded Ag in vitro:   
To compare the intensity and duration of MC-encoded Ag presentation in vitro, 
we transfected a dendritic cell line, DC2.4 (H-2b haplotype), with equimolar amounts of 
VC, FL-Ag or MC-Ag. The Ag cassette encoded the chicken ovalbumin-derived peptide 
SIINFEKL linked to a secretion sequence and a histidine tag (Supplemental Fig. 1). 
Western blot analysis of transiently transfected COS cells revealed the Ag was secreted 
(data not shown). To measure presentation of the SIINFEKL peptide, we analyzed DC2.4 
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cells one, three and five days after transfection for reactivity with 25-D1.16 (Fig. 4a). 
This monoclonal antibody specifically binds SIINFEKL only when presented by H-2Kb 
(46). The frequency of Ag-presenting cells was significantly higher and persisted longer 
in the MC-Ag transfectants as compared to the FL-Ag transfectants (Fig. 4b). The MC-
Ag transfectants also expressed significantly higher Ag levels on each day than the FL-
Ag transfectants. These data demonstrate Ag presentation persists longer, at higher levels, 
and in more DC2.4 cells transiently transfected with MC-Ag as compared to FL-Ag.  
 
Enhanced immunogenicity of MC-encoded Ag in vivo:   
To determine if the enhanced presentation of MC-encoded Ag observed in vitro 
corresponded to increased immunogenicity in vivo, we adoptively transferred equal 
numbers of CD8+ OT-I (Thy1.1+) cells into congenic C57BL/6 (Thy1.2+) mice and 
tracked their responses following DNA immunization. One day after OT-I cell adoptive 
transfers, recipients were tattooed with equimolar amounts of VC, FL-Ag or MC-Ag 
DNA.  Seven days later OT-I cells were identified by their expression of CD8 and the 
allelic marker Thy1.1. The proliferative responses of OT-I cells in mice immunized with 
MC-Ag were significantly greater than the responses in mice immunized with FL-Ag. 
This was true in the spleen (Fig. 5a) and draining lymph nodes (data not shown). To 
assess their functionality, OT-I cells from immunized mice were stimulated briefly in 
vitro with cognate Ag and examined for interferon-γ (IFN-γ) expression. IFN-γ was 
expressed by significantly more OT-I cells from mice immunized with MC-Ag than from 
mice immunized with FL-Ag (Fig. 5b). Moreover, the levels of intracellular IFN-γ tended 
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to be higher in OT-I cells from MC-Ag immunized mice than in FL-Ag immunized mice 
(median fluorescent intensities of 370 versus 235, respectively). 
The in vivo cytolytic activity of OT-I cells was also significantly greater than in 
mice immunized with MC-Ag versus FL-Ag. To assess in vivo cytotoxicity, C57BL/6 
mice were adoptively transferred with OT-I cells and the next day immunized with VC, 
MC-Ag or FL-Ag DNA via tattooing. One week later these mice were injected with equal 
numbers of SIINFEKL-pulsed syngeneic splenocytes labeled with CFSE (CFSEhigh) and 
unpulsed syngeneic splenocytes labeled with 10-fold less CFSE (CFSElow). The loss of 
CFSEhigh (Ag-positive) relative to CFSElow (Ag-negative) cells provided a measure of 
OT-I cytolytic activity in vivo (Fig. 6a) (81). Antigen-specific cytolytic activity in MC-
Ag immunized mice was significantly greater than that in FL-Ag immunized mice (Fig. 
6b). Together these data indicate MC-Ag immunization elicits a significantly greater OT-
I response than does immunization with FL-Ag pDNA.  
 
Discussion: 
 
Our data indicate MC DNAs delivered via tattooing are superior to their FL 
counterparts in terms of the expression levels and duration, as well as the 
immunogenicity, of the proteins they encode. The enhanced levels and duration of protein 
expression we observe in the skin corroborate studies of MC DNA delivered to various 
tissues via other routes for gene therapy (62, 85, 86). The novelty of our report lies in the 
enhanced antigen-specific CD8 T cell response to an epitope encoded by a MC delivered 
transdermally. 
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 Standard pDNA has two components: the bacterial backbone required for 
plasmid propagation in bacteria and the transcription cassette for expression in 
mammalian cells. Removal of the bacterial backbone reduced the size of MC DNA 
relative to pDNA by about half. pDNA size is inversely related to transfection efficiency 
(65) and correspondingly, the transfection efficiency and expression levels of MC are 
higher than pDNA (55, 56, 86). Accordingly we showed cells transfected in vitro with 
MC consistently expressed higher levels of luciferase or Ag compared to parental pDNA 
(Fig. 2a). This was also true in vivo, as evidenced by the > 10-fold levels of luciferase 
activity in mice tattooed with MC-eff compared to FL-eff at all time points measured 
(Fig. 3b). 
A second critical benefit to the removal of the backbone elements is their role in 
gene silencing.  We have shown that the deposition of heterochromatin on the bacterial 
sequences causes the loss of expression that is independent of DNA methylation, CpG 
content, immune cell clearance, and plasmid copy number (59-61, 67)(58). The near 
complete absence of plasmid backbone elements most likely allowed expression of the 
eff transgene encoded by MC DNA to persist throughout the duration of the nine-week 
observation period. It is noteworthy that MC-eff expression at seven weeks was 
comparable to that at one day. This was unexpected because 33-44% of C57BL/6 
keratinocytes are replaced weekly (87) and keratinocytes are the predominant cell type in 
the skin. Moreover, van den Berg et al. reported that 99% of human skin cells transfected 
by pDNA delivered via tattooing were keratinocytes (37). The persistence of eff 
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luciferase expression we observe is consistent with the transfection of longer-lived 
progenitor cells in the skin, such as hair follicle-associated dermal precursors (88).  
Enhanced Ag expression following transdermal administration of MC-Ag DNA 
most likely caused the significant increases in the frequencies of effector OT-I cells. We 
speculate that the Ag provided by the MC DNA and the adjuvant effect resulting from the 
thousands of needle pricks inflicted by the tattoo device combined to produce a local 
microenvironment conducive for naïve CD8+ T cell activation. Because the majority of 
cells transfected by tattooing pDNA are likely keratinocytes, we included a secretory 
signal in the Ag expression cassette. Our rationale was that secreted antigen by 
transfected cells could be internalized by resident antigen-presenting cells in the skin. 
These cells could then migrate to the draining lymph node and cross-present 
SIINFEKL/Kb to naïve OT-I cells. This is consistent with reports that dermal dendritic 
cells are required to stimulate naïve CD8+ T cells upon intradermal immunization with 
pDNA (89).  
Recent studies with pDNA-encoded Ags delivered transdermally suggest, though, 
that transfection of antigen-presenting cells themselves is the key event required to elicit 
specific CD8+ T cell responses. Ag expression in keratinocytes failed to elicit specific 
CD8+ T cell responses upon transdermal delivery of pDNA containing a K14 promoter, 
whereas Ag expression in dermal dendritic cells (via a CD11c promoter) did (54). 
Moreover, depletion of langerin+ dermal dendritic cells ablated the response of CD8+ T 
cells to Ag encoded by pDNA delivered transdermally, suggesting that specific delivery 
of MC to dermal dendritic cells should further enhance immunogenicity upon tattooing. 
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The duration of Ag expression following transdermal immunization with pDNA 
affects CD8+ T cell responses to the encoded Ags (90). Hovav et al. reported that Ag-
presenting cell activity slowly increased over a two-week period following injection of 
pDNA into the ear pinnae of mice (91). Removal of the ear pinnae at various times post-
immunization diminished this activity, and the resultant specific CD8+ T cell responses. 
These data suggest a depot of Ag controls CD8+ T cell expansion at the level of Ag-
presentation. A persistent Ag depot afforded by MC immunization arguably could permit 
sustained CD8+ T cell responses first through activation of naïve CD8+ T cells and then 
persistent reactivation of resultant memory cells. The combination of Ag and 
coadministered proinflammatory cytokines/chemokine all encoded by MC may establish 
a long-lived immunostimulatory microenvironment in the skin, leading to efficacious 
anti-pathogen and anti-tumor immunity. 
In conclusion we show the applicability of the MC to mediate long-term 
expression of transgenes when delivered transdermally.  This clinically relevant delivery 
method and the inherent safety benefits of the non-integrating MC DNA represents a 
novel approach toward DNA-based therapies. 
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Figure 1. Minicircle derivation. (a) Plasmid construct and minicircle generation.  The 
expression cassette contains the human ubiquitin C promoter, genes encoding enhanced 
firefly luciferase (eff) or the chicken ovalbumin-derived SIINFEKL peptide (antigen; 
Ag), and the bovine growth hormone polyadenylation signal. The cassette is cloned 
between the øC31 integrase recognition sites attB and attP in the minicircle producer 
plasmid pMC.BESPX. This plasmid also contains a block of 32 tandem repeats of the I-
SceI homing endonuclease recognition sequence. The full-length (FL) parental plasmids 
are propagated in the ZYCY10P3S2T E. coli strain engineered to express øC31 integrase 
and the I-SceI endonuclease under an arabinose-inducible promoter. Upon induction, 
øC31 integrase activity generates the minicircle (MC) and circular plasmid backbone; the 
latter is subsequently degraded by host exonucleases following linearization by the I-SceI 
endonuclease. (b) Agarose gel electrophoresis analysis of the FL plasmid encoding eff 
(FL-eff) and its MC derivative (MC-eff). Products were linearized by digestion with 
KpnI (FL-eff) or StuI (MC-eff). The arrow indicates residual FL plasmid in the purified 
MC-eff DNA preparation. Sizes of the DNA species are noted next to each band. eff, 
enhanced firefly luciferase; FL-eff, full-length plasmid encoding eff; I-SceI x32, 32 
tandem repeats of the I-SceI homing endonuclease recognition sequence; Kanr, 
kanamycin resistance gene; MC-eff, minicircle encoding eff; mw, molecular weight 
standards; pUC, plasmid origin of replication. 
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Figure 2. Enhanced expression of minicircle-encoded eff in vitro. COS cells were 
transiently transfected with equimolar amounts (1.1 pmol; 2.5 µg MC-eff) of each DNA 
species. A luciferase-specific antibody was used to determine the frequencies of 
luciferase-expressing cells 48 hours later. (a) Flow cytometric analysis of transfected 
COS cells. These are representative flow cytometry contour plots used to determine the 
frequencies of eff-positive COS cells shown in b. (b) Frequencies of luciferase-positive 
COS cell transfectants. Data are presented as mean ± SEM (n =3)(P**<0.01).  eff, 
enhanced firefly luciferase; FL-eff, full-length plasmid encoding eff; MC-Ag, minicircle 
encoding eff; VC, empty full-length plasmid vector control.   
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Figure 3. Enhanced intensity and duration of minicircle-encoded eff expression in 
the skin. The ventral skin on both thighs of C57BL/6 mice was tattooed with equimolar 
(9.2 pmol; 20 µg MC-eff) amounts of empty full-length plasmid vector control (VC), 
full-length plasmid encoding enhanced firefly luciferase (FL-eff), or the eff-encoding 
minicircle derivative (MC-eff).  (a) Representative Xenogen IVIS imaging of in vivo 
luciferase activity (four days post-gene delivery).  The left and right thighs of the first 
four mice show FL-eff and MC-eff activity, respectively. (b) Quantitative long-term in 
vivo luciferase expression.  Animals were imaged daily for 18 days and then weekly from 
days 21 to 63.  The data for the FL-eff and MC-eff cohorts are presented as the mean ± 
SEM (n = 4), corrected for background bioluminescence. Values for the VC cohort (n = 
4) never exceeded background and are not shown. Luciferase activity in the FL-eff cohort 
decayed to background levels on day 42. Luciferase activity in the FL-eff and MC-eff 
cohorts was significantly different (P *<0.05) on each day analyzed except the first day 
(P<0.06). eff, enhanced firefly luciferase; FL-eff, full-length plasmid encoding eff; MC-
eff, minicircle encoding eff; VC, empty full-length plasmid vector control.  
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Figure 4. Enhanced presentation of minicircle-encoded antigen by dendritic cells. 
Cells from the C57BL/6-derived dendritic cell line DC2.4 were transiently transfected 
with equimolar (1.8 pmol) amounts of empty full-length plasmid vector control (VC), 
full-length plasmid encoding the chicken ovalbumin-derived peptide SIINFEKL (FL-
Ag), or the SIINFEKL-encoding minicircle derivative of the full-length plasmid (MC-
Ag). SIINFEKL presented by the MHC class I molecule H-2Kb is an antigen (Ag) 
recognized by specific CD8+ T cells. Cells were analyzed by flow cytometry one, three 
and five days post-transfection for presentation of SIINFEKL by H-2Kb, as determined 
by reactivity with the monoclonal antibody 25.D1-16. (a) Flow cytometric analysis of 
transfected DC2.4 cells. These are representative flow cytometry contour plots (day 
three) used to determine the frequencies of Ag-positive DC2.4 cells shown in b. (b) 
Frequencies of Ag-positive DC2.4 cells.  Data are presented as the mean ± SEM (n = 
3)(P***<0.001). Ag, antigen (SIINFEKL/H-2Kb); FL-Ag, full-length plasmid encoding 
SIINFEKL; MC-Ag, minicircle encoding SIINFEKL: VC, empty full-length plasmid 
vector control.   
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Figure 5. Enhanced activation of antigen-specific CD8+ T cells in vivo following 
immunization with MC-Ag.  C57BL/6 mice were adoptively transferred with 
Thy1.1+/Thy1.2+ CD8+ OT-I cells. OT-I cells bear a transgenic T cell receptor specific 
for the chicken ovalbumin-derived peptide SIINFEKL presented by the MHC class I 
molecule H-2Kb. Twenty-four hours after OT-I cell adoptive transfer, recipients were 
tattooed with equimolar (13.8 pmol; 20 µg MC-Ag) amounts of vector control (VC), full-
length plasmid encoding SIINFEKL (FL-Ag), or the SIINFEKL-encoding minicircle 
derivative (MC-Ag). Mice were sacrificed one week later and their splenocytes analyzed 
by flow cytometry. (a) OT-I cell quantification. Donor OT-I cells were identified by their 
expression of CD8 and Thy1.1 (recipient CD8+ T cells express Thy1.2). (b) Frequencies 
of interferon-γ+ (IFN-γ+) OT-I cells. The frequencies of OT-I cells expressing intracellular 
IFN-γ were determined to assess functional activity. Splenocytes from adoptively 
transferred, immunized mice were incubated with or without SIINFEKL peptide in vitro 
before analysis by flow cytometry for intracellular IFN-γ expression. Data are presented 
as the mean ± SEM (n = 3)(P*<0.05). FL-Ag, full-length plasmid encoding SIINFEKL; 
MC-Ag, minicircle-encoding SIINFEKL; VC, empty full-length plasmid vector control. 
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Figure 6. Enhanced cytolytic activity of antigen-specific CD8+ T cells following 
immunization with MC-Ag.  C57BL/6 mice were adoptively transferred with OT-I 
cells. The next day recipients were tattooed with equimolar (13.8 pmol; 20 µg MC-Ag) 
amounts of empty full-length plasmid vector control (VC), full-length plasmid encoding 
the SIINFEKL peptide (FL-Ag), or the SIINFEKL-encoding minicircle derivative (MC-
Ag) of the full-length plasmid. Control mice were immunized subcutaneously with 
SIINFEKL peptide emulsified in complete Freund’s adjuvant (CFA). Eight days later, 
mice were adoptively transferred with equal numbers of syngeneic splenocytes pulsed 
with SIINFEKL peptide and unpulsed splenocytes. To distinguish them, peptide-pulsed 
and unpulsed splenocytes were respectively labeled with 5 µM and 0.5 µM CFSE. Mice 
were sacrificed 14 hours after cell transfer and their splenocytes analyzed by flow 
cytometry for the frequencies of CFSElow (unpulsed) and CFSEhigh (peptide-pulsed) cells. 
(a) Representative histograms of CFSElow and CFSEhigh cells. The numbers show the 
frequencies of CFSElow and CFSEhigh cells in the CFSE+ populations in immunized mice. 
(b) Antigen-specific in vivo cytolytic activity. The frequency of unpulsed cells (CFSElow) 
was divided by the frequency of peptide-pulsed cells (CFSEhigh) to determine the ratio of 
antigen-negative to antigen-positive target cells in each mouse. These ratios were then 
used to calculate the percent antigen-specific cytolytic activity by the equation: [1-(VC 
ratio/FL-Ag or MC-Ag ratio)] x 100]. Data are presented as mean ± SEM (n = 
5)(P*<0.05;P**<0.01). CFA, complete Freund’s adjuvant; CFSE, 5-(and-6)-
carboxyfluorescein diacetate, succinimidyl ester; FL-Ag, full-length plasmid encoding 
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SIINFEKL; MC-Ag, minicircle encoding SIINFEKL; VC, empty full-length plasmid 
vector control. 
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Supplementary Material: 
Figure S1.  
 
Single letter amino acid sequence of Ag insert. The signal sequence is underlined. The 
10x histidine tag is italicized. The OVA-derived SIINFEKL peptide is bold faced. The 
SIINFEKL epitope is embedded in a larger peptide to facilitate antigen processing. 
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Chapter 4: 
Effect of +36GFP-HA2 Cationic Carrier on in vitro and in vivo Transfection 
Efficiency of Plasmid DNA 
Two major limitations to the use of plasmid DNA for immunotherapy are 
transient protein expression and low transfection efficiency in vivo.  The work presented 
in this chapter focuses on increasing the transfection efficiency of plasmid DNA vaccines 
through the use of highly cationic mutants of green fluorescent protein: +36GFP and 
+36GFP linked to a peptide derived from influenza hemagglutinin (HA2) known to 
enhance nuclear localization.  We show that these cationic carriers bind plasmid DNA 
and significantly increase transfection efficiency in vitro.  In addition, we show that 
+36GFP-HA2 leads to plasmid transfection in vivo, albeit not as efficiently as naked 
plasmid.  By further increasing transfection efficiency we plan to produce plasmid DNA 
vaccines capable of tumor rejection. 
 
Introduction: 
In vivo gene delivery is an umbrella term for the introduction of exogenous nucleic 
acids into multicellular organisms.  Gene delivery has broad appeal because of its 
potential for addition or replacement gene therapy, vaccination and gene silencing (92-
94).  These diverse applications permit its use to study normal and abnormal cell biology, 
and to treat diseases such as cancer.  
DNA can be packaged in viruses or delivered as “naked” plasmid DNA (pDNA) to 
cells in vivo.  pDNA delivery has the advantages of low cost, ease of production, 
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flexibility (several genes can be introduced simultaneously) and safety (e.g. pDNA does 
not cause insertional mutagenesis) (69).  Gene delivery requiring multiple administrations 
is also best served with pDNA because immunity developed against viral proteins blocks 
viral vector delivery (70).  Because of these advantages, pDNA-mediated gene delivery 
in vivo has been evaluated in almost 300 clinical trials to date (95).  Together these trials 
reveal that while pDNA has promise, its efficacy in vivo is limited primarily by poor 
transfection efficiency, transient protein production, and for pDNA vaccines, low 
immunogenicity.  
The efficiency of pDNA transfection in vivo is five to eight orders of magnitude 
lower than that in vitro (78).  This relatively poor efficiency results from pDNA 
degradation by extracellular nucleases, nonspecific pDNA uptake and inefficient 
trafficking to the nucleus (96, 97). To enhance transfection efficiency in vivo, pDNA is 
often complexed to synthetic particles.  For this, the DNA is either complexed with or 
encapsulated into the synthetic carrier producing micro- or nanoparticles.  This technique 
has been widely used for nucleic acid delivery (38)(39)(40).  Most of these complexes are 
formed by the electrostatic interaction between cationic carriers and anionic phosphate 
groups in the plasmid.  Condensation of plasmid DNA by cationic carriers protects DNA 
from degradation by endonucleases and enhances transfection efficiency (both general 
cellular uptake and uptake by APCs in particular) (98).  Examples of synthetic vehicles 
that have been used for DNA delivery include cationic lipids, cationic polymers and non-
cationic polymers such as poly(lactide) or poly(lactide-co-glycolide). 
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We employed a supercharged GFP with a net theoretical +36 charge (+36GFP) as 
a cationic carrier (41).  Lawrence and colleagues have shown that +36GFP has increased 
resistance to aggregation and consequent precipitation.  This highly cationic protein also 
binds DNA and can be used as a transfection reagent in vitro.  To facilitate escape from 
endosomes following cellular uptake, a variant of +36GFP (+36GFP-HA2) was made 
that contains the N-terminal 20 amino acids of the viral influenza hemagglutinin protein 
(HA2) fused to the C-terminus of GFP (99).  The HA2 residues destabilize the endosomal 
membrane and allow escape (100-102).  We show that use of these cationic carriers leads 
to significantly increased transfection efficiency in vitro but lower levels of transfection 
in vivo.  
 
Materials and Methods: 
Design and production of the cationic carriers +36GFP and +36GFP-HA2.  Plasmids 
encoding +36GFP and +36GFP-HA2 were generous gifts from Dr. David Liu, Howard 
Hughes Medical Institute, Harvard University, Cambridge, MA.  The proteins encode a 
6X Histidine tag for purification purposes.  Arctic Express (DE3) bacteria from Agilent 
Technologies, Inc. (Santa Clara, CA) were electroporated with the DNA encoding 
+36GFP or +36GFP-HA2.  A single clone of each was verified by restriction 
endonuclease digestion and glycerol stocks were prepared and frozen at -20°C.       
The proteins, +36GFP and +36GFP-HA2, were expressed in Arctic Express 
bacteria.  Briefly, the bacteria were grown in 2.8L low form flasks containing 1L of LB 
supplemented with carbenicillin until they reached an OD600 of 0.6 to 0.8.  Protein 
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expression was induced by the addition of 0.4mM IPTG and incubation at 15°C for an 
additional 6-8 hours.  Following centrifugation, the bacterial pellets were resuspended in 
ice cold 1.5M NaCl/PBS and sonicated.  Following sonication, the samples were spun 
down at 10,000 x g for 15 min at 4°C and the soluble protein was harvested.  The protein 
was purified using His Gravitrap columns from GE Healthcare (Piscataway, NJ) and 
samples taken throughout the purification process were analyzed by SDS gel 
electrophoresis.  Eluted proteins were dialyzed in 1.5M NaCl/PBS and stored at -20°C 
protected from light.  Protein concentrations were determined spectrophotometrically 
using the extinction coefficient of GFP (M = OD488/(8.33 X 10^4/M X 1 cm)(1cm)). The 
proteins were concentrated using Amicon Ultra-4 Centrifugal Filter Units with 10kDa 
filters from Millipore (Billerica, MA) and stored at -20°C protected from light.   
 
SDS-PAGE.  Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
was used to separate the proteins according to their electrophoretic mobility, a function of 
their molecular weight, or size.  Following protein production, +36GFP and +36GFP-
HA2 were purified over His SpinTrap columns (GE Healthcare) and eluted according to 
the manufacturer’s protocol.  The samples were denatured by boiling for 5min with SDS 
and then run on NuPAGE 4-12% Bis-Tris gradient gels from Invitrogen (Carlsbad, CA).  
The gels were stained with SimplyBlue SafeStain (Invitrogen) for protein visualization.   
 
DNA Plasmid production. The minicircle (MC) DNA encoding enhanced firefly (eff) 
luciferase was constructed and produced from a full-length (FL) plasmid encoding eff as 
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previously described in Chapter 3.  Briefly, MC-eff DNA is devoid of the bacterial 
backbone sequences(62)(95).  The eff was amplified from the pUltra Bright eff 
luciferase+ plasmid (kindly provided by Patrick Hwu, M.D. Anderson Cancer Center 
(Houston, TX)) (79) and inserted into a vector containing the human ubiquitin C 
promoter (UbC; a generous gift from Michael Kyba, University of Minnesota, 
Minneapolis, MN).  
For MC-eff generation, bacteria transformed with FL-eff plasmids (full-length 
plasmid encoding eff) were grown overnight in Terrific Broth supplemented with 
kanamycin (Invitrogen).  The following day MC induction media (fresh LB broth 
containing 0.04 volumes of 1N NaOH and 0.02% L-arabinose (Sigma-Aldrich, St Louis, 
MO)) were added and the culture temperature was decreased from 37˚C to 32˚C for 5-8 
hours in order for the production of MC from FL plasmid.  The culture was centrifuged 
and purified using the PureLink HiPure Filter Plasmid Purification Maxiprep kit 
(Invitrogen) by increasing the recommended volumes of buffers six-fold and purifying 
the MC over four columns. Following elution in water, the plasmids were concentrated to 
4-6 µg/µl by ethanol precipitation, resuspended in water and stored at -20°C. All 
constructs were sequence verified. 
 
Electrophoretic mobility shift assays.  The abilities of the purified +36GFP and +36GFP-
HA2 proteins to bind DNA were tested in electrophoretic mobility shift assays (EMSA). 
Briefly, a 0.7% agarose gel was pre-run at 4°C for 1 hour at 93V (to remove any potential 
contaminants).  120ng of the DsRed2 plasmid (a gift from Dr. Marc Jenkins, University 
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of Minnesota, Minneapolis, MN) was mixed with either +36GFP or +36GFP-HA2 in 
PBS at molar ratios of 0, 30:1, 100:1, 200:1 or 300:1 (protein to DNA) which 
corresponds to charge ratios of 0, 0.1:1, 0.3:1, 0.7:1, or 1:1 (positive to negative charge) 
and incubated at room temperature for 30 minutes protected from light.  Following this 
incubation, the complexes were electrophoresed on 0.7% agarose gels at room 
temperature at 93V for 100 minutes without loading dye.  The gels were stained in 50 ml 
of 0.6 µg/ml ethidium bromide for 15 minutes and analyzed using UV light.   
 
HEK293T cells.  HEK293T cells (a gift from the Polunovsky lab at the University of 
Minnesota, Minneapolis, MN) were maintained in complete Dulbecco’s modified Eagle’s 
medium (Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen) at 37°C 
with 5% CO2.   
 
HEK293T cell transfections with +36GFP or +36GFP-HA2 and flow cytometry analysis.  
Adherent HEK293T cells were dissociated from tissue culture flasks with TrypLE 
Express (Invitrogen) and plated in 6 well tissue culture-treated plates (BD Biosciences, 
San Jose, CA) at equal numbers (2-5 x 105 cells) per well without antibiotics.  The 
following day, the cells were treated with equimolar (0.23 nmol) amounts of protein, 
+36GFP or +36GFP-HA2, and incubated for 48 hours.  The cells were harvested and 
analyzed for GFP expression by flow cytometry on a BD FACSCalibur flow cytometer 
using BD CellQuest Pro software (BD Biosciences) and analyzed with FlowJo software 
(Tree Star, Inc., Ashland, OR).   
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HEK293T cell transfections with +36GFP or +36GFP-HA2 and MC-eff plasmid.  
Adherent cells were dissociated from tissue culture flasks with TrypLE Express 
(Invitrogen) and plated in 80 cm2 tissue culture-treated flasks (Thermo Scientific, 
Rochester, NY) at 1.5 x 106 cells per well without antibiotics.  Two days later, the cells 
were incubated with +36GFP or +36GFP-HA2 (with or without MC-eff plasmid).  
Briefly, +36GFP or +36GFP-HA2 was incubated with MC-eff (a luciferase-encoding 
plasmid) for 30 minutes at room temperature at a charge ratio of 0.7:1 (positive to 
negative) as determined by EMSA (20 µg MC-eff with either 54 µg +36GFP or 60 µg 
+36GFP-HA2).  The cells were harvested 48 hours later for luminescence assays on a 
plate reader.   
 
Measurements of transfection efficiency in vitro.  Two days after transfection with 
+36GFP or +36GFP-HA2 (with or without MC-eff plasmid), 1 x 106 HEK293T cells 
were resuspended in 100 µl Reporter Lysis Buffer (Promega, Madison, WI), sheared by 
repetitive passage through 29 gauge needles and centrifuged at 12,000 x g for 15 seconds 
in 1.5 ml Eppendorf tubes to pellet debris.  Supernatant (20 µl) was added to 15 µl 
Luciferase Assay Reagent (Promega) substrate and 35 µl PBS in a 96 well plate, mixed 
and read on a Synergy HT Multi-Detection Microplate Reader (BioTek, Winooski, VT) 
for 1 second each using a 590/20 nm bandpass filter.  The data were analyzed using Gen5 
Data Analysis Software (BioTek).   
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Mice.  Four to eight week old female BALB/c mice were purchased from the Jackson 
Laboratory (Bar Harbor, ME). All mice were housed under specific pathogen free-
conditions at the University of Minnesota (Minneapolis).  All animal procedures were 
carried out according to protocols approved by the Institutional Animal Care and Use 
Committee. 
 
Plasmid DNA immunizations (with and without +36GFP-HA2). Mice were anesthetized 
and their inner hind legs were shaved and wiped with 70% ethanol.  The mice were 
immunized with the specified amounts of plasmid DNA (with or without +36GFP-HA2) 
or with +36GFP-HA2 alone in 10-15 µl volumes.  The plasmids were incubated at room 
temperature with +36GFP-HA2 for 30 minutes prior to immunization.  The plasmids 
were delivered transdermally using a Cheyenne Hawk PU II tattoo device (Unimax 
Supply Co. Inc., New York, NY) set at 110 Hz using 9-point needles.  The needle was 
adjusted to a depth of 0.5mm.  DNA was delivered over an area of approximately 1cm2 
for 30 seconds. 
 
Bioluminescence measured in vivo.  Mice were imaged for bioluminescence using a 
Xenogen IVIS Imaging System and the data were analyzed using Living Image 2.5 
Software (Caliper Life Sciences, Hopkinton, MA).  Briefly, mice were injected 
intraperitoneally with 100 µl of 30mg/ml luciferin and anesthetized with isoflurane. 
Bioluminescence was measured for 5 min.   
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Statistical analysis. All statistical analyses were performed by the unpaired two-tailed 
Student’s t-test unless noted otherwise. 
 
Results: 
Production of the cationic carriers: 
In an effort to increase plasmid DNA transfection efficiency, we first produced 
two cationic carriers, +36GFP and +36GFP-HA2 (Figure 1A) (41).  We chose these 
proteins since they bind DNA and can be used as transfection reagents in vitro. They can 
also be tracked by fluorescence.  +36GFP and +36GFP-HA2 were produced in Arctic 
Express bacteria and purified using His Gravitrap columns.  Samples taken throughout 
the purification process were analyzed by SDS gel electrophoresis (Figure 1B-C).  The 
purified proteins are homogeneous and +36GFP-HA2 migrated slightly slower than 
+36GFP, consistent with their masses of 32.66 and 29.41 kDa, respectively.  The carboxy 
terminus of +36GFP-HA2 contains the first 20 amino acids of the viral influenza 
hemagglutinin protein (HA2) which facilitates endosomal escape(102, 103).  The proteins 
were concentrated and stored at -20°C protected from light.   
 
DNA binding ability of the cationic carriers: 
  To test the ability of the cationic carriers to bind DNA and to determine the 
optimal binding ratio, we used an electrophoretic mobility shift assay (EMSA).  Plasmid 
DNA was mixed with either +36GFP or +36GFP-HA2 in PBS at molar ratios of 0, 30:1, 
100:1, 200:1 or 300:1 (protein to DNA) which corresponds to charge ratios of 0, 0.1:1, 
Tattooing 
-d1 
OT-I readout 
OT-I transfer 
d0 d3 d6 d12 
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0.3:1, 0.7:1, or 1:1 (positive to negative) and incubated at room temperature for 30 
minutes.  Following incubation, the complexes were electrophoresed on agarose gels and 
analyzed using UV light.  As the protein binds to the DNA, the DNA’s size and charge 
change, thereby leading to a shift in its position in the gel.  Condensation of DNA on the 
cationic carriers also decreases the ability of ethidium bromide to intercalate between the 
DNA strands. This shift in mobility and ultimate loss in ethidium bromide labeling are 
indicative of DNA/protein binding and are used to determine the optimal amount of 
protein to bind the DNA completely.  As Figure 2 shows, the DNA was completely 
bound by protein at a molar ratio of 200:1 (protein to DNA) or a charge ratio of 0.7:1 
(positive to negative).              
 
Ability of cationic carriers to transfect cells with plasmids in vitro: 
To confirm that the +36GFP and +36GFP-HA2 proteins can bind cells, HEK293T 
cells were incubated with either +36GFP or +36GFP-HA2 for 48 hours and were 
analyzed by flow cytometry.  As shown in Figure 3, 100% of the cells were positive for 
+36GFP and +36GFP-HA2, indicating that the proteins were able to bind the cells.  
To determine if +36GFP and +36GFP-HA2 could transfect cells in vitro, +36GFP 
or +36GFP-HA2 was first incubated with MC-eff (a luciferase-encoding plasmid) at a 
charge ratio of 0.7:1 (positive to negative) as determined by EMSA.  HEK293T cells 
were incubated with the protein/DNA complexes for 48 hours and then the cells were 
harvested.  Following harvest, luminescence was analyzed on a plate reader.  As shown 
in Figure 4, both +36GFP and +36GFP-HA2 led to internalization and expression of the 
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plasmid encoding luciferase.  However, there was not a significant difference in 
luciferase expression between the two proteins.  
 
Ability of cationic carriers to transfect cells with plasmids in vivo: 
We next tested the ability of +36GFP-HA2 to enhance transfection efficiency in 
vivo.  MC-eff was incubated +36GFP-HA2 at a charge ratio of 0.7:1 (positive to 
negative).  Following incubation, either MC-eff alone, +36GFP-HA2, or a mix of MC-eff 
and +36GFP-HA2 were administered to BALB/c female mice intradermally using a 
tattoo device.  The mice were imaged 48 hours later for bioluminescence.  We found that 
+36GFP-HA2 led to transfection and expression of MC-eff in vivo, but was not as 
efficient as plasmid alone (Figure 5). 
 
Discussion: 
These studies show that the +36GFP and +36GFP-HA2 cationic carriers bind 
pDNA and transfect cells in vitro.  McNaughton and colleagues have shown that +36GFP 
internalization is via endocytosis and is dependent on electrostatic interactions with 
sulfated cell surface proteoglycans (99).  This process is energy-dependent, clathrin- and 
caveolin-independent and requires actin polymerization.  Additionally, they showed that 
+36GFP-HA2, but not +36GFP, was able to transfect mammalian cell lines (HeLa, 
IMCD, 3T3-L and PC12) with pDNA.  We show that both +36GFP and +36GFP-HA2 
are able to transfect mammalian cells (HEK293T) with pDNA.  However, +36GFP-HA2 
did not result in significantly higher in vitro transfection efficiency than +36GFP as 
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expected based on McNaughton’s results.  Also, McNaughton showed that 2 µM 
+36GFP-HA2 led to transfection in several cell lines while 200 nM was insufficient for 
transfection, whereas we found that 95 nM was sufficient for transfection with both 
+36GFP and +36GFP-HA2. 
The differences in transfection efficiency between +36GFP and +36GFP-HA2 
may be due to variability among the cell lines or between the DNA.  There is great 
variability in transfection efficiency among different cell types and cell line and several 
cell lines including adipocytes and neuronal cells have shown resistance to cationic lipid 
transfection reagents (104, 105).  Lavorini-Doyle and colleagues have shown that this 
difference in transfection efficiency occurs after pDNA internalization via endocytosis 
and may be due to inability to escape the endosome or inability to enter the nucleus 
(106).  HA2 residues destabilize the endosomal membrane and allow escape, but may not 
facilitate import into the nucleus (100-102).  Additionally nuclear pDNA transcription is 
affected by the physiological state of the cell (107).  Therefore, differences in endosomal 
escape, nuclear internalization or the physiological state among cell lines may account for 
the differences in transfection efficiencies between +36GFP and +36GFP-HA2.  Finally, 
the use of different DNAs may have contributed to the differences in transfection 
efficiencies between McNauton’s results and ours.  McNaughton used the pSV-β 
galactosidase plasmid (Promega, Madison, WI) which is 6820 bp whereas we used MC-
eff which is approximately 3200 bp.  Smaller plasmids have been shown to have higher 
transfection efficiencies than larger plasmids (108) and this may have contributed to the 
increased transfection efficiency that we found following +36GFP administration.  
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In addition, use of +36GFP-HA2 led to lower transfection efficiencies in vivo than 
plasmid alone.  This may be due to the positively charged carrier binding to negatively 
charged extracellular matrix components on the cell surface and therefore preventing 
plasmid uptake and expression.  Van den Berg and colleagues have shown that by 
shielding the surface charge using PEGylation, they can improve protein expression by 
more than 55 fold (109).  Future optimization, such as that previously described, may 
lead to increased transfection efficiency of carrier protein/plasmid complexes in vivo, 
thereby leading to more efficacious DNA vaccines in a clinical setting.  
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Figure 1.  Protein sequence, expression and purification. +36GFP and +36GFP-
HA2 were expressed in E. coli and purified using His Gravitrap columns from GE 
Healthcare (Piscataway, NJ).  A. Protein sequence of +36GFPHA2 (mutated residues 
in +36GFP relative to GFP are bold faced; HA2 peptide is underlined).  B. Protein 
expression and purification fractions for +36GFP-HA2: (1)Protein molecular weight 
standards, (2) Flowthrough, (3) Wash #1, (4) Wash #2, (5) Elution.  C. Purified 
+36GFP-HA2 (1) and +36GFP (2). 
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Figure 2.  DNA binding ability of +36GFP and +36GFP-HA2. +36GFP or 
+36GFP-HA2 were incubated for 30 minutes with DsRed2 plasmid and were found to 
bind DNA at a molar ratio of 200:1 (0.7:1 positive to negative charge ratio).  (1) DNA 
ladder, (2) DsRed2 plasmid alone, (3-6) DsRed2 plasmid with various molar ratios of 
+36GFP, (7-10) DsRed2 plasmid with various molar ratios of +36GFP-HA2.   
  102 
  
+36GFP +36GFP-HA2 
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Figure 3.  Ability of +36GFP and +36GFP-HA2 to bind cells in vitro. HEK293T cells 
were incubated with either +36GFP, +36GFP-HA2 or no protein for 48 hours.  The 
cells were harvested and analyzed by flow cytometry for GFP fluorescence.   
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Figure 4.  Transfection efficiency of +36GFP and +36GFP-HA2 in vitro using a 
luciferase-encoding plasmid. +36GFP or +36GFP-HA2 with or without MC-eff (a 
luciferase-encoding plasmid) were incubated with HEK293T cells for 48 hours.  
Following incubation, 1 x 10^6 cells were lysed and luminescence was detected on a 
plate reader.   
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Figure 5.  Transfection efficiency of +36GFP-HA2 in vivo.  MC-eff alone, 
+36GFP-HA2 alone or MC-eff with +36GFP-HA2 was administered to mice 
intradermally to the inner hind leg using a tattoo device.  48 hours after 
immunization, the mice were imaged for bioluminescence.  Only the highest amount 
of +36GFP-HA2 led to luciferase expression (see mouse #3, left leg).  A. Mouse 
image.  B. Graph of data in A.       
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Chapter 5: 
Concluding Remarks 
Although there are currently over 1,000 cancer vaccines in clinical trials (132 are 
DNA vaccines), only one has received FDA approval (110).  Provenge (Dendreon Corp., 
Seattle, WA), a dendritic cell based vaccine, was approved in April, 2010 for the 
treatment of castration-resistant prostate cancer (111, 112).  The problem plaguing most 
cancer vaccines is their low immunogenicity in humans.  Two major barriers to the 
immunogenicity of DNA vaccines are transient protein expression and poor transfection 
efficiency.  The objective of this work was to overcome these limitations and thereby 
increase the efficacy of DNA vaccines. 
First, we established a platform in which to optimize DNA vaccines for cancer 
therapy by addressing both the plasmid DNA vaccine components and the route/strategy 
for administration of the vaccines (Chapter 2).  These studies showed that the DNA 
plasmids encoded functional proteins that were expressed both in vitro and in vivo.  
Furthermore, plasmid immunization via a tattoo device resulted in functional antigen-
specific CD8+ T cell responses in vivo.  Lastly, we found that secretion of the plasmid-
encoded protein was not necessary.  Consistent with this finding, Elnekave and 
colleagues recently discovered that directly transfected DCs are responsible for CD8+ T 
cell activation following intradermal DNA administration, thereby making the secretion 
of plasmid encoded proteins unnecessary (54).   
Next, we addressed the limitation of transient protein production.  Levels of 
plasmid DNA-encoded proteins drop rapidly following intradermal plasmid 
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administration (37).  Therefore, multiple immunizations are required to achieve adequate 
immune responses.  By increasing protein expression, we may reduce the need for 
multiple immunizations and produce more potent immune responses.  As a result, DNA 
vaccination may become quicker, cheaper and more effective.   
In Chapter 3 we overcame transient protein expression by removing essentially all 
of the bacterial backbone (which contains transcriptionally repressive chromatin), thereby 
producing minicircle (MC) DNA.  We showed that the MC results in increased protein 
expression and in increased transfection efficiency in vitro and in both increased protein 
expression and increased duration of protein expression in vivo (protein expression for 
63+ days with the MC compared to 5 or 6 days as shown by Bins and colleagues (53)).  
The increase in transfection efficiency seen following MC immunization is likely due to 
its decreased size as several studies have shown that smaller plasmids result in higher 
transfection efficiencies (55, 56, 65, 108).  Furthermore, MC immunization resulted in 
significantly greater percentages of functional antigen-specific CD8+ T cells and in 
greater antigen-specific killing in vivo, showing an enhanced antigen-specific immune 
response compare to the FL DNA.   
Decreasing the size of the DNA resulted in increased transfection efficiency, but 
to further increase transfection efficiency and to decrease plasmid degradation, we tested 
the ability of two cationic carriers (+36GFP and +36GFP-HA2) to increase plasmid 
transfection efficiency (Chapter 4).  Interestingly, these studies showed that both +36GFP 
and +36GFP-HA2 bound pDNA and transfected cells in vitro whereas previous research 
showed that only +36GFP-HA2 led to in vitro transfection (99).  The ability of +36GFP 
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to transfect 293T cells with MC may be due to variability in transfection efficiency 
among cell lines or to the smaller size of the DNA we used (less than half the size of the 
other DNA).  In addition, use of +36GFP-HA2 led to lower transfection efficiencies in 
vivo than plasmid alone.  This may be due to the positively charged carrier binding to 
negatively charged extracellular matrix components on the cell surface and thereby 
preventing plasmid uptake and expression.  Future optimization, such as shielding the 
surface charge using PEGylation (109), may lead to increased transfection efficiency in 
vivo.  
One limitation to this work is that the immune responses were measured using an 
OT-I adoptive transfer system.  Adoptively transferring congenically labeled T cells into 
mice enables easy detection and monitoring of the resultant immune response (82).  
However, the number of precursor cells is elevated above that of a naïve animal and 
therefore does not accurately reflect the endogenous response.  To overcome this 
limitation, future work will include characterizing the endogenous response to the DNA 
vaccines using tetramers and T cell functional assays including enzyme-linked 
immunosorbent assay (ELISA), enzyme-linked immunosorbent spot (ELISpot) assay and 
cytotoxicity assays.  Tetramers bind antigen-specific T cells and can be used to directly 
detect these cells using flow cytometry.  ELISA and ELISpot assays can be used to 
monitor effector cytokine production in vitro following antigen stimulation whereas 
cytotoxicity assays can be used to directly assess antigen-specific killing in vitro. 
Future directions include further enhancing DNA vaccine immunogenicity.  One 
way to increase the immunogenicity is to encode an adjuvant within the DNA.  The MC 
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DNA used in these studies included T cell antigens but did not include an adjuvant.  By 
adding Hsp70 or another potent adjuvant, we may significantly increase its 
immunogenicity.  Adjuvants are especially important for therapeutic vaccines since it is 
necessary to overcome immune tolerance for a cancer vaccine to be successful.  
Additionally, different adjuvants are known to result in different immune responses, such 
as aluminum salts lead to antibody production (113) whereas monophosphoryl lipid A 
results in both B and T cell responses (114-116).  Therefore, it is important to choose an 
adjuvant that will result in a CD8+ T cell response for a cancer vaccine.  Another way to 
increase immunogenicity is to use a DNA prime followed by a protein or peptide boost.  
Two recent studies show that using a DNA-prime, protein/peptide-boost results in 
significantly greater immune responses compared to DNA vaccination alone (117, 118). 
In closing, we have overcome the limitation of transient protein expression and 
have modestly increased transfection efficiency.  Through the addition of adjuvants and 
by further enhancing transfection efficiency through cationic carrier optimization, we 
plan to increase the immunogenicity of DNA vaccines. 
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